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Human respiratory syncytial virus (RSV) is the leading cause of severe 
respiratory tract infection in infants, children, the elderly and immunocompromised 
patients, commonly resulted in bronchiolitis and/or pneumonia. The estimated global 
annual infection and mortality figures for RSV are 64 million and 160,000 
respectively. Up till now, there is still no licensed vaccine nor safe and effective 
antiviral strategy available against RSV. The development of new therapy to the 
disease is urgently needed. Due to the great chemical diversity, secondary plant 
metabolites serve as a major source of potential antiviral agents. In this study, two 
purified plant compounds, seven commercially available phytochemicals, as well as 
the water and ethanol extracts of nine medicinal plants were screened for their 
anti-RSV activity by observing their inhibition on RSV-induced cytopathic effect and 
their cytotoxicity were examined by MTT assay. A purified compound from 
Wikstroemia indica, designated as daphnoretin, and a lectin purified from Narcissus 
tazetta var. chinensis, designated as NTL, as well as the ethanol extract of Adina 
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pilulifera possess potent antiviral activity and low cytotoxicity. Subsequently the 
ethanol extract of pilulifera was further fractionated and the ethyl acetate fraction 
was found as the most potent anti-RSV fraction. The half maximal inhibition 
concentration (IC50) of the ethyl acetate fraction of A. pilulifera and daphnoretin were 
2.22 and 5.87 }ig/ml, respectively, as studied by plaque reduction assay. 
Antiviral activity of NTL (13 kDa) and the other two N. tazetta proteins 
were also investigated. The two mannose-binding proteins NTM2 (15.2 kDa) and 
NTM3 (6.7 kDa) were isolated from Narcissus tazetta cultivar by ammonium sulfate 
precipitation, mannose-agarose affinity chromatography and fast protein liquid 
chromatography. N-terminal amino acid sequence of NTM2 revealed considerable 
homology to NTL. From the in vitro antiviral study, NTL was found less cytotoxic 
and being the most potent protein with an IC50 value of 2.30 |Lig/ml in plaque 
reduction assay. 
Mechanistic studies showed that daphnoretin, NTL and the ethyl acetate 
fraction of A. pilulifera exerted different modes of antiviral action. When the samples 
were added during different phases of RSV infection cycle, daphnoretin could slightly 
inhibit early viral infection but mainly on the later events. NTL inhibited both early 
and later events of the infection cycle, while the ethyl acetate fraction of A. pilulifera 
inhibited the events of later phase. 
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In conclusion, the three candidates were shown for the first time that they 
possess anti-RSV activity and have different modes of action. This study might 
provide scientific information for the future development of the three candidates as 
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Chapter 1 General Introduction 
Chapter 1 
General Introduction 
1.1 Respiratory Syncytial Virus (RSV) 
Human respiratory syncytial virus (RSV) is the leading cause of serious 
upper and lower respiratory tract infection in infants, children, older adults and people 
of all ages with compromised respiratory, cardiac, or immune systems. It is a 
ubiquitous pathogen in all human populations, and the seasonality of RSV outbreak 
varies from place to place, which occurs during the winter and spring months in 
Europe, North America, and countries with temperate climates, while in the tropical 
countries it may occur in rainy season. RSV infects up to 65 % of infants in the first 
year of life, and virtually all infants are infected by 2 years of age. Bronchiolitis 
and/or pneumonia are the most common results of first infections, and approximately 
80 % of childhood bronchiolitis cases and 50 % of infant pneumonia are due to RSV 
infection (Black, 2003). The estimated global annual infection and mortality figures 
for RSV are 64 million and 160,000 respectively (World Health Organization, 2008). 
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1.2 RSV biology 
RSV was first isolated in 1956 from a chimpanzee with mild upper 
respiratory signs and was named "Chimpanzee Coryza Agent" (Morris et al., 1956). 
In the following year, antigenically identical viruses were isolated from two infants 
both with lower respiratory disease (Chanock et al., 1957). The virus was renamed 
Respiratory Syncytial Virus in recognition of its characteristic cytopathogenic effect 
(syncytium formation) in tissue culture (Chanock & Finberg, 1957). 
RSV is classified in the genus Pneumovirus of the Paramyxoviridae family. 
The RSV virion is typically spherical with diameter of 150 to 200 nm (Figure 1.1), or 
it can exist in filamentous form with up to 400 nm in length (Figure 1.2). The 
determinants of these two morphological forms and the roles of such particles in virus 
transmission and pathogenicity are not completely understood (Gower et al., 2005). 
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Figure 1.1 Transmission electron microscopic photo of spherical RSV budding 
(VB) from plasma membrane (PM) (Adapted from Brown et al., 
2002). 
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Figure 1.2 Transmission electron microscopic photo of filamentous RSV (VF) 
budding from plasma membrane (PM) (Adapted from Brown et al., 
2002). 
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RSV virion is surrounded by a lipid envelope derived from the plasma 
membrane of the host cell during budding. Its genome is composed of single-stranded, 
negative-sense ribonucleic acid (RNA) of 15,200 nucleotides containing 10 genes 
which encode for 11 proteins (Figure 1.3 and Table 1.1). The fusion (F), attachment 
(G), and small hydrophobic (SH) proteins are the three integral membrane proteins on 
the envelope. The F, G and nonstructural proteins (NSl and NS2) interact with the 
matrix (M) protein layer on the internal surface of the envelope. The helical 
nucleocapsid, which is associated with the nucleoprotein (N), phosphoprotein (P) and 
large (L) proteins, is located inside the M protein layer (Figure 1.4). 
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Figure 1.3 Genomic structure of RSV (Modified from Eastern et al., 2004). 
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Figure 1.4 Respiratory syncytial viral structure (Modified from Hacking & 
Hull, 2002). 
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Table 1.1 RSV genes, proteins and protein functions (Modified from Hacking 
& Hull, 2002). 
Genes Proteins Functions 
NSl NSl 
Anti-interferon a and p activity 
NS2 NS2 
N N Essential for transcriptional activity 
P P Essential for transcriptional activity 
M M Viral assembly 
SH SH Function unknown 
G G Viral attachment to host cell 
F F Viral entry and syncytia formation 
M2-1 Transcription elongation factor 
M2 
M2-2 Viral transcription regulation 
L L RNA polymerase 
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The replication cycle of RSV begins with the attachment of RSV to host cell 
surface, which is believed to be mediated by the interaction between a viral protein 
and a cellular receptor. The G protein of RSV was identified as the viral attachment 
protein when G protein-specific polyclonal antibody blocked adsorption of RSV to the 
surface of target cells (Levine et al., 1987). However, a study found that G protein is 
not essential for cell attachment, but acts as an accessory protein which increases the 
efficiency of the process (Teng & Collins, 1998). Moreover, the cellular receptor for 
G protein has not been identified, although there is abundant evidence that RSV binds 
to cellular glycosaminoglycans (GAGs) (Bourgeois et al., 1998; Teng et al., 2001). 
GAGs are unbranched polysaccharide chains associated with most mammalian cells. 
The GAG types that appear to be important for RSV infection in HEp-2 cells are 
heparan sulfate (HS) and chondroitin sulfate B (CS-B) (Hallak et al., 2000). The 
interaction between G protein with GAGs facilitates the viral entry, but alternative 
pathways may also be involved (Crim et al., 2007). 
After successful attachment, fusion of the viral envelope or infected cell 
membrane with the plasma membrane of uninfected cells can be carried out in the 
presence of F protein, and the process is enhanced by the G protein. Nucleocapsid is 
then released into the cytoplasm, and transcription of the viral messenger RNA 
(mRNA) is carried out by the L protein, which is an RNA polymerase, together with 
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the N and P proteins, which are essential for the L protein to carry out its function. 
The virus genome contains one polymerase entry site (leader or promoter sequence) at 
the 3’ end of the genome. The polymerase complex travels along the genome until it 
reaches the conserved start sequence of each gene and initiates transcription. During 
the process, methylation of the immature mRNA occurs, probably also through the 
action of L protein, to produce a cap structure that ensures translation on host 
ribosomes. Transcription of a gene terminate when the polymerase reaches a 
conserved stop sequence that contains a short run of U residues, and thus a 
polyadenylated (poly(A)) tail is added to the mRNA (Easton et al., 2004). Only a 
portion of polymerase (about 50%) can progress to the next gene and starts 
transcription, and dissociated polymerase can only reinitiate transcription by 
translocation to the 3' leader sequence. As a result, mRNA transcripts of genes more 
proximal to the 3' leader sequence are more abundant. The termination and 
reinitiation process is poorly understood, but it has been shown that the M2-1 protein 
is essential for full-length virus mRNA production (Fearns & Collins, 1999). 
After viral products have been generated, replication of the viral genome can 
be carried out, which also involves the action of the L, N, and P proteins. The 
polymerase binds to the 3'end promoter sequence of the RNA genome and initiates 
RNA synthesis. Once initiated, the polymerase is committed to continue to the end of 
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the template to produce an antigenome. As the 5, end of the RNA genome contains an 
antisense copy of the promoter sequence, the 3’ end of the antigenome possesses the 
promoter sequence for the next round of replication to generate the negative-sense 
single-stranded RNA for progeny virus genomes. 
After considerable amount of progeny RSV genomes are produced, the viral 
assembly occurs. The M2-2 proteins accumulated during infection may involve in 
switching the virus from replication to assembly (Ahmadian et al., 1999). New 
nucleocapsids are formed when N, P, L and M2-1 protiens are associated with the new 
RNA genomes, and then through the M2-1 proteins interact with M proteins, which 
have been associated with G proteins on cell membrane. M proteins function by 
rendering the nucleocapsid transcriptionally inactive before packaging and promote 
the association of the nucleocapsid complex with the region of cell membrane that 
will become the envelope after budding, which appears to be the reverse process of 
penetration. Besides, viral particles are transmitted directly from cell to cell without 
exiting from the cell membrane, via the cell fusion process mediated by F protein and 
RhoA (Pastey et al., 2000). 
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1.3 RSV strains 
Naturally occurring variants of RSV fall into two antigenic groups, A and B, 
which are identified on the basis of their differential reactivity with monoclonal 
antibodies and later confirmed on the basis of gene sequence showing particular 
divergence within the sequence of the G gene (Garcia-Barreno et al., 1989). One 
strain tends to dominate during an individual epidemic in an individual location, 
although sometimes both strains can be isolated from different patients in the same 
area (Hall, 2001). 
Several subtypes of the two strains have been identified on the basis of the 
variability within the G protein (Cane, 2001; Hall, 2001). Antibodies developed in 
patients against RSV are specific to the G protein of the particular strain involved in 
infection. It is speculated that the variability within the G proteins among various 
RSV strains and subtypes hampers the effectiveness of the host immune protection 
against infections by another RSV strain. It also makes the production of an effective 
vaccine against RSV quite difficult (Wilson et al., 2000; Cane, 2001; Hall, 2001). 
A number of studies suggested that strain A may results in more virulent 
infections than strain B. In a 2-year prospective analysis of 157 hospitalized infants, it 
was found that strain A RSV infections were associated with greater illness severity 
than strain B infections (McConnochie et al., 1990), In the study, objective clinical 
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findings and laboratory measurements were used to derive and validate a severity 
index to quantitate illness severity. Another larger scale study, which involved 265 
hospitalized infants assessed over a 3-year period, showed similar results (Walsh et al., 
1997). Among infants without underlying medical conditions, strain B RSV infection 
rarely required ventilatory support, in contrast to strain A infections, and had 
significantly lower severity indices. 
1.4 RSV pathogenesis and host antiviral responses 
RSV is transmitted through close contact with infected individuals or direct 
contact with infectious secretions. The incubation period is 2-8 days after initial 
contact. Shedding of virus begins within a day after infection, often before the onset 
of major symptoms. Shedding of RSV appears to correlate roughly with the age of the 
infected individual, the severity of the infection, and whether the infected person is 
immunocompromised (Black, 2003). 
RSV induces direct cytopathic effect on lung epithelial cells, leading to the 
impairment of specialized functions such as cillial motility and sometimes epithelial 
destruction. Peribronchiolar mononuclear cell infiltration accompanied by submucosal 
edema and mucus secretion are commonly observed. These resulted in bronchiolar 
obstruction with patchy atelectasis and areas of compensatory emphysema (Openshaw, 
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2005). There are also many linger effects reported after RSV infection, including 
acute otitis media and persistent wheezing due to airway hyperreactivity that may 
contribute to the development of asthma (Black, 2003; Martinez, 2003). 
Multicellular organisms have various strategies against viral infection. The 
first line of defense is cell-mediated immune response that involves the generation of 
cytokines such as interleukins (IL) and tumor necrosis factor (TNF), which activate 
and recruit macrophages, natural killer (NK) cells, and neutrophils that clear the 
infected cells by phagocytosis as well as by inducing cell lysis. The second line of 
defense is the humoral immune response that involves cytotoxic T lymphocytes 
(CTL), antibodies, and numerous cytokines. However, serious damage or death can 
occur before adequate immune responses arise, thus a third level of defense exists — 
induction of interferons (IFNs) by the presence of viral nucleic acids (Roulston et al., 
1999). These immune responses, however, lead to the enhancement of disease severity, 
which may be relevant not only to childhood bronchiolitis, but also to obstructive lung 
diseases in adults. 
While virus-specific immune responses are largely responsible for protection 
against RSV-associated lower respiratory tract infections as well as recovery from 
infection, immune responses to RSV are short-lived, so reinfection can occur 
throughout life (Maggon & Barik, 2004). The severity of the disease generally 
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decreases with subsequent reinfections, and although reinfections are common, their 
frequencies decrease with age. 
1.5 Prevention of RSV infection 
7.5.7 Vaccines 
Although the importance of RSV as a respiratory pathogen has been 
recognized for over 40 years, a vaccine is not yet available because of several 
problems inherent in RSV vaccine development. RSV has an RNA genome, and all 
RNA genomes accumulate mutations at a high rate due to the lack of replicational 
proof-reading mechanisms, which presents a significant challenge in designing a 
reliable vaccine against various RSV strains (Domingo & Holland, 1997). RSV-host 
interactions involve a large and complex network of signaling pathways that must 
play important roles in the manifestation of the RSV disease, but are only beginning 
to be unraveled. The immunopathology of RSV is also complex (Hacking & Hull, 
2002), including the relatively unique phenomenon of vaccine-enhanced disease. An 
experimental formalin-inactivated RSV vaccine (Pfizer Lot 100) tested in infants in 
the mid 1960s was immunogenic but failed to offer protection against RSV infection. 
The immunized infants experienced a more severe disease in subsequent RSV 
infection, with two of the vaccinated infants died (Kim et al., 1969). In fact, 
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immunologic immaturity of infants, the declining immune system of the elderly and 
the compromised immune system of some high risk patients are the major issues 
regarding the development of RSV vaccine. It is thus reasonable to develop a vaccine 
for pregnant women in the last trimester of pregnancy in order to pass a large maternal 
antibody load to infants, or produce a vaccine that would augment antibody 
production in the elderly or immunocompromised patients who has been infected by 
RSV previously. 
A number of vaccines in fact have been progressed in the development to 
animal models and toxicology studies and some to clinical trials. Two main types of 
vaccines have been formulated and investigated, including live attenuated virus 
primarily for young infants (Murphy & Collins, 2002), and RSV subunit vaccines for 
people who have already experienced primary RSV infection, such as the elderly and 
older RSV-seropositive children with chronic cardiac or pulmonary disease. Table 1.2 
shows the RSV vaccines under development. 
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Table 1.2 RSV vaccines under development (Maggon & Barik, 2004). 
Target 
Product Characteristics Company/Agent Status/Phase 
population 
LA Cpts 248/404 Infants Wyeth; NIAID CTII 
A2cpts 
LA 248/404-SH ^^^^^^^ Wyeth; MAID CT II 
RB/HPIV3-
LA 似 V AZB Infants Medlmmune PT 
LA RA2, M2-2 Infants NIAID PT 
LA 2B33F Infants NIAID PT 
SV PFPl Elderly Wyeth CT I 
SV PFP2 Elderly Wyeth CT II 
SV PFP3 Elderly Wyeth CT II 
Pierre Fabre 
SV BBG2Na Elderly CT III 
Medicament 
SV FG487808 Elderly GSK CT I 
SV F+G Elderly Aventis CT II 
LA: live attenuated; SV, subunit vaccines; CT, clinical trial; PT, preclinical trial. 
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Live attenuated RSV vaccine would mimic natural infection, and could be 
applied intranasally, thereby making it more suitable to young infants. Several 
strategies have been employed for the development of the vaccine, including the 
creation of host range mutants, cold passaged (cp) mutants, and temperature-sensitive 
(ts) mutants. The cp and ts mutants could only replicate at temperature below 37 
thus their growth would be inhibited at normal body temperature. The weakened 
strains are expected to be avirulent and causing limited infection or illness. However, 
clinical trials of these vaccine candidates were initially discouraging. They are either 
under-attenuated (cpRSV and RSVts-1) or over-attenuated (RSVts-2). Later on some 
cpts viruses (produced under combined conditions used for producing the cp and ts 
mutants) were shown immunogenic and phenotypically stable (Polack & Karron， 
2004). 
The F and G protein of RSV can induce production of neutralizing and 
protective antibodies. As less antigen variation is present in the F protein than in the G 
protein of RSV within the same subgroup, and the F protein contains conserved 
domains between both subgroup A and B, the F protein has been the focus of trials of 
various subunit vaccines. Purified F protein (PFP) has shown the greatest promise. 
PFPs were evaluated in phase I-II clinical trials with demonstrated safety and 
immunogenicity. Besides the PFP vaccines, recombinant vaccines consisting of F, G 
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and M subunits has also entered the Phase I clinical trials (Polack & Karron, 2004). 
1.5.2 Passive anti-RSV antibodies 
Another approach to achieve immunoprotection against RSV is the use of 
passive antibodies. Two forms of passive immunoprophylaxis are available for 
prescription, including RSV immune globulin intravenous (RSV-IGIV, RespiGam®) 
and palivizumab (Synagis� ) . 
RSV-IGIV is a polyclonal concentrated neutralizing antibody produced from 
the sera of adult humans. A randomized, prospective study of administration of 
RSV-IGIV to high-risk infants showed significant reductions in the rate and severity 
of lower respiratory tract infection, the need for hospitalization and days spent in 
intensive care (Hemming et al., 1987; Rodriguez et al, 1997; Simoes et al., 1998). It 
is given by a 2-4 hours intravenous infusion and costs about US$5000 per infusion 
(Maggon & Barik, 2004). However, the use of RSV-IGIV has several limitations. It is 
a blood-derived product so there is a danger of transmission of infectious pathogens. 
Besides, it interferes with the measles-mump-rubella vaccine and varicella vaccine. 
Side effects of RSV-IGIV include fever, rash, hypotension and, in rare cases, 
anaphylaxis. 
Palivizumab is a humanized anti-F monoclonal antibody (mAb) composed of 
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human (95 %) and murine (5 %) antibody sequences. It received approval from the 
United States Food and Drug Administration (FDA) in 1998 and is now approved in 
over 50 countries as a standard for prevention of RSV in high-risk infants such as 
premature and those with chronic lung and congenital heart diseases. Palivizumab 
neutralizes a broad range of RSV strains in animal models, and in a phase III clinical 
study in 1502 high-risk infants, it reduced the incidence of hospitalizations by 55 % 
(The IMpact-RSV Study Group, 1998). Palivizumab is given as an intramuscular 
injection, and only monthly injections are required during the RSV seasons, making it 
more convenient than RSV-IGIV. An estimated 253,808 infants have received more 
than 1 million doses of palivizumab prophylaxis in the 4 years followed FDA 
approval, and postmarketing safety surveillance confirmed the pre-licensure safety 
profile of palivizumab used in more than 250,000 infants (Romero, 2003). Although 
palivizumab is expensive, up to US$4000 per RSV season (Stevens & Hall, 2004), it 
is considered as cost-effective in some studies (Elhassan et al., 2006; Nuijten et al., 
2007). 
Further modification of palivizumab generates a more potent 
second-generation mAb, motavizumab (Numax^^), which is currently under 
evaluation in Phase III clinical trials. Besides, more recently, a third generation mAb, 
Numax-YTE, has been generated and aimed to extend the serum half-life in humans. 
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It is hoped that the antibody can reduce the frequency of dosing (Wu et al., 2008). 
Table 1.3 shows the anti-RSV antibodies that are either in market or under active 
development. 
Table 1.3 Anti-RSV antibodies in market and under development (Maggon & 
Barik, 2004). 
Sales 2003 / 
Product Characteristics Company 
status 
RespiGam® 
Immunoglobulin Medlmmune Negligible 
(RSV-IGIV) 
Synagis® Human anti-F � ^ Medlmmune $849 M 
(Palivizumab) glycoprotein 
Felvizumab Human anti-F Phase III 
GSK Scotgen 
(RSHZ19) glycoprotein completed 
CSL/Oravax Phase III 
HNK20 (MoAb) Immunoglobulin 
Acambis completed 
Numax™ 
Monoclonal antibody Medlmmune Phase III 
(Motavizumab) 
R19 Monoclonal antibody Epicyte Preclinical 
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1.6 Treatment for RSV infections 
Attempts to develop effective therapy for RSV infections have been ongoing 
for as long as the virus has been recognized. However, no specific anti-RSV drug has 
been discovered yet. In clinical management, supportive therapies, including 
hospitalization, supplemental oxygen delivery, nasopharyngeal suctioning, and in the 
most severe cases, intubation and mechanical ventilation are employed. Other 
strategies include the use of bronchodilators, corticosteroids, and ribavirin. 
L6.1 Ribavirin (Virasole®) 
Aerosolized ribavirin is the only antiviral preparation approved by FDA for 
treating severe lower respiratory tract RSV infections in the high risk hospitalized 
infants and young children, and it is a synthetic compound structurally related to 
ribonucleoside guano sine with broad spectrum antiviral activity against many DNA 
and RNA viruses. It inhibits viral multiplication by several mechanisms, including 
inhibition of viral polymerase, inhibition of 5' cap formation of mRNA, inhibition of 
inositol monophosphate dehydrogenase, and immune-modulating action (Maggon & 
Barik, 2004; Bosch et al., 2007). The effect of ribavirin has been reviewed in many 
studies, but the results are inconsistent and contradictory. Administration of ribavirin 
is very labor intensive and possesses some hazards to caregivers (Black, 2003). Also, 
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the drug is expensive and its cost-effectiveness must be evaluated (Maggon & Barik, 
2004). In 1996, the American Academy of Pediatrics recommended that ribavirin 
should be used after deliberation by physicians for children with substantial 
comorbidities (such as cardiopulmonary disease or immunosuppressive disease or 
therapy) or those with exceptionally severe RSV infection (Black, 2003). 
1,6,2 Other antiviral strategies 
Due to the absence of available vaccine or other immunoprophylatic agents, 
and the uncertain beneficial effect of ribavirin on the improvement of RSV disease in 
hospitalized patients, new strategies for therapeutic intervention during moderate to 
severe RSV disease are clearly needed. Antiviral compounds targeting different stages 
of viral cycle can be used according to various stages of disease. Antiviral drug that 
targets viral attachment and/or fusion can restrict early viral infections or further 
spreading of the virus. Viral replication inhibitors, such as ribavirin, can be used at a 
later time after initial infection and limit viral titre in patients. These antivirals have 
higher potential to be developed as successful antiviral agents for clinical use. A 
variety of antiviral compounds have been identified and tested for their ability to 
impair RSV replication in vitro and in vivo. 
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1.6.2.1 Attachment inhibitors 
The attachment of RSV to target cells is largely mediated by the G protein. 
The process also requires the presence of GAGs on cell surface. Molecules that 
interfere with RSV to bind to the cell surface GAGs can inhibit the attachment 
process. Large polyanionic molecules such as heparin, sulphated polysaccharides like 
dextran sulphate, and sulphated polymers such as polyvinylalcohol sulfate are able to 
compete with the binding of RSV to cell surface GAGs and thereby inhibit viral 
replication (Hosoya et al., 1991; Krusat & Streckert, 1997). Another molecule that has 
similar anti-RSV action as the polyanions is the RhoA derived peptide comprising 
amino acids 80 to 94 of the intracellular GTPase RhoA. The inhibition of RSV by this 
peptide is dependent on both the net charge and multimerization of the peptide. 
Successful inhibition largely occurs to RSV with G protein, suggesting that RSV G 
protein is a primary target of peptide binding (Budge et al., 2004). 
Some heteropolyanions called polyoxometalates which contain early 
transitional metal ions could cluster with the surrounding oxygen atoms, and they are 
shown to have in vitro anti-RSV activity (Barnard et al., 1997; Shigeta et al., 2003). 
Among them, HS-058 appears to inhibit RSV adsorption as well as syncytium 
formation (Shigeta et al., 2006). 
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1.6.2.2 Fusion inhibitors 
Entry of RSV to host cells involve fusion of the virus envelop to host cell 
membrane. This process is largely mediated by the F protein, which also involves in 
the formation of syncytia after RSV replication to allow virus spreading through cell 
to cell fusion. 
RSV-specific fusion inhibitors, such as peptides derived from different 
domains of the RSV F protein, block RSV-induced syncytium formation at 
concentrations as low as 0.015 \iM (Lambert et al., 1996). Some small molecules that 
inhibit the fusion processes of RSV have been reported, including CL387626, 
RFI-641, BMS-433771, JNJ2408068 (also known as R-170591), RD3-0028, and 
VP-14637. All these molecules have been shown to have inhibitory effects on early 
virus-cell fusion. It was reported that CL387626, a disulfonated stilbene, significantly 
inhibited pulmonary replication of RSV when administered intranasally 4 or 5 days 
prior to virus challenge, but it failed to significantly inhibit pulmonary RSV 
replication when administered after virus challenge (Wyde et al., 1998). So the 
compound is prophylactic, but prolonged prophylactic activity was observed in the 
study, indicating that the drug was not readily degraded from the lungs and this is 
hazardous to the host. Further modification of the drug yielded RFI-641, which is 
more potent and no persistency of antiviral activity in lung tissues observed. Both the 
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intranasal and aerosol administration of RFI-641 in in vivo studies showed reduction 
of the viral load (Huntley et al.’ 2002; Weiss et al., 2003). BMS-433771 is a 
benzimidazole derivative which is orally bioavailable, and presumably interferes with 
the functional interaction of the C- and N-terminal heptad repeats in the F protein by 
binding tightly in the pocket formed in the N-terminal heptad repeat region (Cianci et 
al., 2005). JNJ2408068, another benzimidazole derivative, can protect cotton rats 
from pulmonary RSV infection by aerosol exposure for 15 minutes, one day prior or 
one day after virus inoculation (Wyde et al., 2003). However, the drug shows long 
tissue retention times in several species of experimental animals (rat, dog, and 
monkey). The drug has been further modified to form molecules that have shorter 
half-lives in the lung tissues, but shows a drop in the RSV inhibitory effect. Thus, 
further optimization of those molecules and more in vivo tests are needed (Bonfanti et 
al, 2007). RD3-0028 is a compound with a benzodithiin structure. It is shown to 
inhibit late stage RSV replication cycle events and is not directly virucidal (Sudo et 
al., 2001). Pharmacokinetics of RD3-0028 was tested in rats by aerosol treatment, 
which might be a useful route for delivering the drug to RSV-infected patients (Sudo 
et al., 2002). The triphenol compound VP-14637 inhibits RSV through a similar 
mechanism to that of JNJ2408068, which involves an interaction between the 
compound and a transient conformation of the RSV F protein (Douglas et al., 2003; 
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Douglas et al., 2005). The drug also exhibits good selective antiviral efficacy both in 
vitro and in vivo (Wyde et al., 2005). 
1.6.2.3 Replication inhibitors 
RNA polymerase of RSV comprised of at least five viral components 
including the genomic RNA and the L, N, P, and M2-1 proteins. Multiple 
protein-protein and protein-RNA interactions mediate the assembly and activity of the 
RNA polymerase. Thus, it is a complex that is rich in potential antiviral targets. An 
assay that specifically measures the synthesis of RSV transcripts in vitro through 
capture of the mRNA poly(A) tails was developed. By using this assay, a novel RSV 
RNA polymerase inhibitor (Compound A) was discovered (Mason et al., 2004). 
Compound A causes a general impairment of mRNA synthesis by RNA polymerase 
as the synthesis of all major RSV mRNA species are equally inhibited. Several 
derivatives of Compound A that have improved anti-RSV potency in vitro also exhibit 
activity in a mouse mode (Liuzzi et al., 2005). This class of inhibitors may block 
synthesis of RSV mRNAs by inhibiting guanylylation of viral transcripts because 
short transcripts produce in the presence of inhibitor in vitro do not contain a 5'cap, 
and thus the synthesis of full-length RSV transcripts is prevented. 
Another compound, YM-53403, potently inhibited the replication of RSV 
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strains belonging to both A and B subgroups in vitro (Sudo et al., 2005). 
Time-dependent drug addition test showed that the compound inhibited RSV life 
cycle at around 8 hours post-infection. Moreover, a single point mutation in the L 
protein was found in two YM-53403-resistant viruses, further suggesting that early 
transcription and/or replication of RSV genome may be inhibited. 
There are also other methods of regulation of viral gene expression. One such 
approach is the use of antisense drugs, which are synthetic oligo deoxynucleotides 
that are 15-20 nucleotide long and able to bind to small segments of the target mRNA 
that have the complementary sequence to the oligo nucleotide. Such binding may lead 
to a direct inhibition of translation if the antisense oligo is designed against the 
translational regulatory sequences of the mRNA (such as ribosome-binding site), or 
lead to degradation of the targeted mRNA by RNase. It was reported antisense oligos 
targeted against RSV NS 1 and NS2 proteins diminished the expression of these two 
proteins (Maggon & Barik, 2004). The use of antisense oligos for viral translation 
inhibition was tested by two companies, but the results were not promising. On the 
other hand, antisense oligos can be coupled to 2’,5’-oligoA, which recruits cellular 
2',5'-oligoA-dependent RNase L that degrades the target viral RNA (Torrence, 1999). 
These oligos have shown potent inhibition of RSV replication in vitro (Adah et al, 
2001), and in vivo using an African green monkey model of RSV infection (Leaman 
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et al., 2002). Concomitant use of ribavirin and 2',5'-oligoA-coupled antisense oligos 
was reported to lead to a reduction in RSV replication in vitro, even both were used at 
suboptimal concentrations (Xu et al., 2004). There are no publications describing 
antisense therapy in human clinical trials. Further improvements are needed to 
overcome some technical problems with antisense oligos, such as drug delivery to 
target cells, stability of the drug and cellular toxicity. 
RNA interference is another gene-expression-mediated antiviral strategy. 
The mechanism involves an evolutionary conserved RNA metabolism pathway found 
in all eukaryotes, in which sequence-specific double-stranded RNA (short interfering 
RNA; siRNA) lead to specific degradation of target RNA and thus gene expression is 
regulated. The antiviral effect of RNA interference was first demonstrated against 
RSV (Bitko & Barik, 2001), which has been subsequently reproduced against other 
viruses. For RSV, this approach has been used to target the P and NSl genes. siRNA 
designed to abolish either the P or NSl gene led to inhibition of RSV replication in 
vitro and lowered viral titres in lung tissues in animal models by intranasal application. 
Airway reactivity was also decreased (Zhang et al., 2004; Bitko et al., 2005). 
However, siRNA may show various degrees of nonspecific, off-target effects at high 
concentrations, and the limited delivery of siRNA to susceptible or infected host 
remains a major challenge to the use of this approach as RSV therapeutic options. 
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1.6.2.4 Ethnobotanic medicines 
Over the centuries, medicinal plants have been widely used for the treatment 
of various diseases and formed the basis of traditional medicaments in China, India, 
Africa as well as many other civilizations. It is speculated that only about 6 % of the 
250,000 plant species on earth have been screened for biological activities and 
evaluated as a source of drugs (Verpoorte, 2000). Thus there is a great potential in 
finding more plants as a source of medicinal agents. The aims of using plants as 
sources of therapeutic agents are 1) to isolate bioactive compounds that can be used 
directly as drugs, e.g. morphine, taxol; 2) to identify bioactive compounds of novel or 
known structures as lead compounds for semisynthesis to produce new entities of 
higher activity and lower toxicity, e.g. oxycodon (based on morphine), taxotere (based 
on taxol); 3) to use as pharmacologic tools, e.g. mescaline; 4) to use the whole plant 
or part of it as a herbal remedy, e.g. Ginkgo biloba, Echinacea. Approaches to 
selecting plants for drug discovery programs include random selection followed by 
chemical screening and/or by one or more biologic assays, follow-up of biologic 
activity reports or ethnomedical uses of plants, as well as the use of databases such as 
the NAPRALERT database that contains information on 43,879 higher plant species 
covering ethnomedical, chemical, and pharmacologic uses (Fabricant & Farnsworth, 
2001). 
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Although numerous compounds have been tested against different viruses, in 
the market there are only 37 licensed antiviral drugs available (Chattopadhyay & Naik, 
2007). The problems of side effects, viral latency, resistance to currently available 
antiviral drugs, as well as rapid spread and emergence of viral diseases like acquired 
immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV) 
and severe acute respiratory syndrome (SARS) caused by SARS-associated 
coronavirus (SARS-CoV) urged intensive screening of more potential antiviral 
candidates. Besides small molecules from medicinal chemistry, natural products are 
major sources of novel therapeutic agents for viral diseases. Chemical diversity of 
secondary plant metabolites resulted from plant evolution may be even more superior 
to that found in synthetic combinatorial chemical libraries. The interest in developing 
medicinal plants as antiviral agents has begun decades ago. The Boots drug company 
(Nottingham, England) screened 288 plants for anti-influenza activity and 12 of them 
were found able to suppress virus amplification (Chantrill et al, 1952). Later on more 
screening programmes were launched to evaluate the antiviral activity of medicinal 
plants for in vitro and in vivo assays. Table 1.4 shows some recent experimental 
results of medicinal plants that exhibits antiviral activities against various viruses. 
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Chapter 1 General Introduction 
The basic step for evaluation of the therapeutic potential of a medicinal 
plant is to prepare crude cellular lysate of the plant matrix followed by the extraction 
of various components that might have potential medicinal value or might be used as 
lead compounds for further synthesis of novel related compounds. The common class 
of antiviral compounds present in medicinal plants include phenolics and polyphenols, 
coumarins, flavonoids, terpenoids and essential oils, quinones, tannins, lignans, 
alkaloids, lectins, polypeptides, and sugar-containing compounds. Some of these are 
reviewed in the following section. 
1.6.2.4.1 Anti-RSV medicinal plant components 
1.6.2.4.1.1 Phenolics and polyphenols 
Polyphenols extracted from Blumea laciniata, Elephantopus scaber, Laggera 
pterodonta, Mussaenda pubescens, Schefflera heptaphylla and Scutellaria indica 
inhibit RSV with the mean concentration of 50 % inhibition (IC50) of 12.5 to 32 jig/ml, 
and selective indices (SI) ranging from 11.2 to 40 (Li et al., 2004). Moreover, three 
known phenolic compounds, (-)-(R)-nyasol, its derivative, as well as broussonin A 
were isolated from the rhizomes of Anemarrhena asphodeloides, and their activities 
against the A2 strain of RSV were being higher than that of ribavirin (Bae et al., 
2007). 
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A biphenolic depsides 3,5-dicaffeoylquinic acid (Figure 1.5) were isolated 
from Flos lonicerae (Ojwang et al., 2005) and was shown effective to inhibit at least 
four RSV subtype A and one RSV subtype B at a low micromolar level without 
significant cytotoxicity observed. The compound was able to reduce RSV titers by � 1 
log at dose 12.5 and 25mg/kg/day, and by >2 log at lOOmg/kg/day in a cotton rat 
model. The compound was also isolated from Schefflera heptaphylla (Li et al., 2005b), 
and it was found that antiviral action of the compound was specific against RSV but 
not effective against influenza A, coxsackie B3, and herpes simplex type one (HSV-1) 
viruses. Besides, it appeared that the compound could inhibit RSV fusion. 
H Q ^ C O O H 
g r n 9 7, 
7" T 5 q f 
、 8' h H ^ L 
H c r i ^ i ^ W 〇 H 
O H O H 
Figure 1.5 Structure of 3,5-dicaffeoylquinic acid (Ojwang et a!.’ 2005). 
1.6.2.4.1.2 Flavonoids 
It has been reported that some flavonoids such as catechin, quercetin, and 
hesperetin can inhibit replication of some viruses, including RSV (Kaul et al., 1985). 
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Moreover, two new iridoid glycosides and three phenylpropanoid glycosides, namely 
luteoside A, luteoside B and luteoside C, from Barleria prionitis and the root of 
Markhamia lutea respectively, have potent in vitro anti-RSV activity (Chen et al., 
1998; Kernan et al., 1998). In another study, five groups of biflavonoids 
(amentoflavone, agathisflavone, robustaflavone, rhusflavanone and 
succedaneflavanone) were isolated from Rhus succedanea and Garcinia multiflora, 
which exhibit various effects against herpes viruses and respiratory viruses, including 
RSV (Liu et al, 1999). 
SP-303, a flavonoid polymer isolated from the latex of Croton lechleri, has 
antiviral activity against RSV in cotton rats (Wyde et al., 1993) and in primate model 
(Soike et al, 1992). The study of the mode of action of SP-303 shows that RSV 
penetration was inhibited, suggesting that SP-303 might be able to bind to specific 
RSV proteins, which may sterically hinder RSV penetration (Barnard et al., 1993). 
R 
I T I OH 
OH R \ 
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Figure 1.6 Proposed structure of SP-303 (Adapted from Wyde et al” 1993). 
-jj> -
Chapter 1 General Introduction 
1.6.2.4.1.3 Terpenoids and essential oils 
Essential oils are components of fragrance of plants and are phenolic 
compounds. The oils that are highly enriched in isoprene are called terpenes, and 
when contain additional elements like oxygen, they are called terpenoids. Two highly 
active pure triterpenoids purified from an extract of the long leafstalk of the 
compound leaf of Schefflera heptaphylla exhibited antiviral activities against RSV, 
influenza A, coxsackie B3, and herpes simplex virus type 1 viruses (Li et al,, 2007). 
Dysoxylins A to D, belonging to the tetranortriterpenoid family, were isolated from 
Dysoxylum gaudichaudianum and were found to exhibit potent antiviral activity 
against RSV in vitro with EC50 (50 % effective concentration) ranged from 1 to 4 
lig/ml (Chen et al, 2007). 
1.6.2.4.1.4 Lectins 
1.6.2.4.1.4.1 General introduction to lectins 
Lectins are a class of proteins that bind carbohydrates but do not 
biochemically modify the carbohydrates to which they bind. They are separated 
from immunoglobulins though lectins also possess apparent specificity of binding. 
Another characteristic of lectins is that they agglutinate cells and precipitate 
polysaccharides and glycoproteins. Despite hundreds of monosaccharides can be 
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found in nature, the large majority of lectins recognize just a few monosaccharides, 
mainly mannose, glucose, galactose, fucose, A^-acetylglucosamine, 
A^-acetylgalactosamine and A^-acetylneuraminic acid, as well as numerous 
oligosaccharides composed of these monosaccharides. Lectins are structurally diverse. 
They are oligomeric proteins composed of subunits, one or more of which carries a 
sugar binding site. Lectins occur in all classes and families of plants, animals and 
microorganisms, although not necessarily in every genus or species (Sharon & Lis, 
2003). 
1.6.2.4.1.4.2 Historical aspects of lectins 
Lectin was discovered by Hermann Stillmark in 1888 during the search for 
toxic principle in castor beans (Ricinus communis) and the initial detection of the 
agglutinating effect of castor bean extracts to blood cells from different animals. 
Using the very primitive isolation methods available at that time, a hemagglutinating 
powder was obtained, which was named “ricin”. It was later discovered that “ricin’’ 
was a mixture of a weakly agglutinating protein toxin (still known as ricin) and a 
nontoxic agglutinin {Ricinus communis agglutinin, RCA). In 1919, James B. Sumner 
isolated the pure lectin concanavalin A from jack beans {Canavalia ensiformis). In 
1936, he discovered that in addition to the agglutinating activity, concanavalin A 
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could also precipitate glycogen from solution. Besides, hemagglutination by 
concanavalin A was inhibited by sucrose, suggesting that there might have a reaction 
of the plant protein with carbohydrates on the red cell surfaces. Systematic screening 
of plant extracts for agglutinating activities led to a breakthrough in hematology. In 
the late 1940s, it was reported that certain seeds contain agglutinins specific for 
human blood group antigens. The chemical nature of the blood group determinants as 
oligosaccharides was then delineated (Riidiger & Gabius, 2001). Over the past few 
decades, many researches have been carried out to study the occurrence of lectins in 
various organisms. Their structures, biosynthesis, functions in nature, genetics, and 
applications in biology and medicine have also been under intense investigation. 
1.6.2.4.1.4.3 Applications of lectins 
Lectins are widely employed in research for diverse purposes. In the past, 
lectins were used for blood typing, fractionation of lymphocytes and bone marrow 
cells for bone marrow transplantation, and for chromosome analysis in human 
cytogenetics. Nowadays, they are invaluable tools for the detection, isolation and 
characterization of glycoproteins and other glycoconjugates, for cell and tissue 
histochemistry and for examination of cell surface changes during physiological and 
pathological processes such as cell division and cancer development. 
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In fact, some researches show the antiviral activities of plant lectins. Many 
enveloped viruses carry carbohydrate-containing proteins on their surface. As the 
mediators of the receptor binding and membrane fusion of the virus with the host cell, 
these glycoproteins are important to the infection process. Therefore, they are 
attractive therapeutic targets for the development of novel antiviral therapies. With the 
ability of lectins to specifically bind to carbohydrates, scientists are interested in 
testing various lectins against many viruses such as HIV, HSV, influenza virus, 
SARS-CoV and RSV (Balzarini et al.’ 1992; Luo et al., 2007; van der Meer et al., 
2007). In case of RSV, it is found that the post-adsorption events of RSV in HeLa 
cells can be inhibitied by plant lectins from List era ovata and Urtica dioica (Balzarini 
et al., 1992). Moreover, the mannose-binding lectin isolated from Smilax glabra is 
able to inhibit RSV-induced cytopathic effect on HEp-2 cells (Ooi et al., 2004). 
1.7 Objectives of the project 
The development of RSV vaccine and the search for new antivirals against 
RSV is still ongoing. There is still a great potential in finding novel and potent 
antiviral agents from plants. For RSV, such researches may not be as many as those 
for the more life-threatening diseases such as AIDS, influenza, hepatitis B, and SARS. 
Therefore, the objectives of the present study are: 
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1) To screen various medicinal plant extracts and purified phytochemicals for 
anti-RSV activity, 
2) To study the mode of antiviral action of the selected potential anti-RSV 
compounds. 
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Chapter 2 
Screening of medicinal plants and phytochemicals for antiviral 
activity against R S V 
2.1 Introduction 
With the absence of available vaccine and specific anti-RSV drug, RSV 
infections could only be prevented by the use of expensive passive antibodies or 
treated by the non-specific, broad spectrum antiviral drug ribavirin as well as other 
supportive cares. Therefore, there is an urgent need for finding novel potent 
anti-RSV agents. Plants have formed the basis for traditional medicine system that 
have been used in many countries for thousands of years. Natural products from 
plants have provided one of the most important sources of lead compounds for the 
pharmaceutical industry and nearly 40 % of modern drugs are derived from natural 
sources (Jassim & Naji, 2003). At present, only a small fraction of the available 
plant species have been screened for their biological activities and evaluated 
phytochemically, and even less have been screened for their antiviral potential. Thus 
there is a great potential in finding anti-RSV agents from plants. 
Previously, some in vitro studies were carried out to screen some plants for 
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their anti-RSV activities. In one study, certain traditional Argentine medicinal plants 
for treating infectious diseases {Polygonum punctatum, Myrcianthes cisplatensis and 
Lithraea molleoides) were shown to be able to inhibit RSV with median effective 
dose range from 78 to 120 |ig/ml and maximal non-cytotoxic concentration greater 
than 250 |ig/ml (Kott et al., 1999). In another study, the extracts of 44 traditional 
Chinese medicinal herbs which had been orally administered for the treatment of 
respiratory infectious diseases were evaluated for their anti-RSV activities (Ma et al., 
2002), and among these, 25 herbs show potent antiviral activities against RSV with 
IC50 values ranging from 6.3 to 52.1 |ig/ml and SI values ranging from 4.0 to 32.1. 
Two of the plants Sophora flavescens and Scutellaria baicalensis were further 
studied for their antiviral components, and subsequently eleven and four compounds 
were isolated, respectively. Among the compounds from S. flavescens, anagyrine, 
oxymatrine and sophoranol showed potent anti-RSV activities with same IC50 value 
of 10.4 |ig/ml and SI values of 24, 12, and 24, respectively. Wogonin and oroxylin A 
from S. baicalensis were shown to have IC50 values of 7.4 and 14.5 jiig/ml, and SI 
values of 16.1 and 4.0 respectively. 
Previously in our laboratory, twenty one medicinal herbs traditionally used 
in southern China for the treatment of skin and respiratory diseases were also 
screened and six aqueous extracts from Blumea laciniata, Elephantopus scaber, 
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Laggera pterodonta, Mussaenda pubescem, Schefflera heptaphylla and Scutellaria 
indica exhibit anti-RSV activity with IC50 values lower than 50 fig/ml and SI values 
higher than 10 (Li et al., 2004). The SI value of X heptaphylla was found higher 
than that of ribavirin, and so isolation of active compounds were conducted and two 
caffeoylquinic acids were found to possess potent anti-RSV activity, that may 
resulted from inhibition of virus-cell and cell-cell fusion (Li et al., 2005b). 
As previously many medicinal plants used for treating respiratory diseases 
were screened for their anti-RSV activity by another research group of our 
laboratory, in this study for my M.Phil degree programme, some others medicinal 
plants that have been used for treating other diseases were screened for their in vitro 
anti-RSV activities. These include Adina pilulifera (Lam.) Franch. ex Drake (水團 
花)，Adina rubella Hance (水楊梅)，Arctium lappa L.(牛蒡)，Ardisia chinensis 
Benth (小紫金牛)，Poly gala aureocauda Dunn (黃花侄[j 水蓮)，Polygonatum 
odoratum (Mill.) Druce (玉竹)，Pandanus amaryllifolius Roxb.(香蘭葉),Serissa 
serissoides (DC.) Druce (白馬骨)，and Wikstroemia indica (L.) C. A. Mey (了哥王). 
Adina pilulifera roots have been used for treating dysentery, enteritis, 
dropsy, eczema and ulcers (Shi & Min, 2003). Adina rubella is a Chinese folk 
medicinal plant used as an antibacterial and anti-cough agent. Its ethanol extract was 
also reported to inhibit some tumors (Fang et al,, 1995). 
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Arctium lappa is also known as burdock, which is originated in Japan. It 
has been used as folk medicine as it possess antibacterial, fungicide, diuretic, 
antioxidative, and anxiolytic activities. It was also found able to inhibit platelet 
aggregation and HIV actions (Gentil et al., 2006). 
Ardisia chinensis is a shrub that is traditionally used as medicinal plant 
among the Yao minority in Southern China for the treatment of icterohepatitis. It is 
also used in remedies for tuberculosis, emptysis, orchitis and trauma. Recent 
researches shown that the aqueous extract of the plant could inhibit duck hepatitis B 
virus in vitro, and a polysaccharide of the plant exhibited a significant antiviral 
effect against Coxsackie B3 (Cox B3) virus, a virus that can cause a wide variety of 
human diseases, including fatal myocarditis, pericarditis, dilated cardiomyopathy, 
aseptic meningitis and acquired diabetes (Su et al, 2006). 
Poly gal a aureocauda have been used as folk medicine in Southern China. 
The root of P. aureocauda has been shown to possess antiviral, hypolipidemic and 
antioxidant activities (Li et al., 2008). Polygonatum odoratum has been one of the 
herbs traditionally used in Korea and China as a treatment of type II diabetes 
mellitus, hypertension, and cardiovascular diseases (Choi & Park, 2002). 
Pandanus amaryllifolius is a plant grown in Southeast Asia that has 
scented leaves, which are used as a food flavoring and in traditional medicine in the 
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Malaysia, the Philippines, Thailand, and Indonesia. Some chemical constituents of 
Pandanus species have been used as remedy for toothache and rhematism, and as 
diuretic and cardiotonic (Takayama et al, 2002). 4-hydroxybenzoic acid has been 
isolated from the hot water extract of the root of this plant and was shown to have 
hypoglycemic activity (Peungvicha et al., 1998). 
Serissa serissoides is used among different minorities of China in treating 
dyspepsia and hepatitis. Water soluble extract of the plant had marked inhibition 
effects on HBeAg and HBsAg expressed by 2.2.15 cells (Chen et al., 1999). Its 
methanol extract was also found to have anti-tumor activity (Zhang & Sun, 2006). 
Wikstroemia indica root is used as a folk remedy for arthritis, tuberculosis, syphilis 
and pertussis (Ko et al., 1993). Besides, daphnoretin 
(7-hydroxy-6-methoxy-3,7'-dicoumaryl ether) had been isolated from the plant 
(Chen et al, 1981). 
In addition to the medicinal plant extracts, two purified plant compounds 
including daphnoretin and Narcissus tazetta lectin (NTL), five flavonoids including 
quercetin, naringin, morin, baicalein and luteolin, as well as two well known 
purified phytochemicals including cinnamic acid and gallic acid were also made 
available for antiviral assays. 
Screening of potential antiviral agents involves the use of rapid and simple 
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procedures to measure both antiviral activities as well as cytotoxicity in cell cultures. 
For antiviral assays, target-specific or non-target specific screening approaches can 
be employed. Target-specific approaches are biochemical assays of ligand-target 
interactions designed to focus on specific viral or cellular molecules, proteins or 
enzymatic activities. These cell-free assays can be developed to high throughput 
screening with increased screening capacity in a limited amount of time. High 
throughput screening involves highly automated and computerized operations to 
handle sample preparation, assay procedures and data processing. Various 
technologies are available for high throughput screening, including 
fluorescence-based assays, nuclear-magnetic resonance, affinity chromatography, 
and DNA microarray (Liu et al,, 2004). 
Non-target specific approaches, on the other hand, screen for multiple 
targets in the context of a natural infection, which may reveals novel targets and 
structures not captured in target-specific assays. In the current RSV study, as the 
vims induces the formation of syncytia in infected cell cultures, antiviral activity can 
also be monitored by observation of this cytopathic effect. This non-target specific 
method is rather qualitative, and so the results are more reproducible. Moreover, the 
test is relatively less labour intensive. However, as this is a cell-based assay, it is 
limited to certain virus strain/target cell combinations that result in highly cytopathic 
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infections. Besides, such assay usually limited to stable cell lines that can be easily 
manipulated and propagated, and more resources and time have to be spent on 
keeping the cell line. The status of the cells used in antiviral assay may greatly affect 
viral infection, and false-positive results may be obtained if the cells are in 
unfavorable condition for successful viral infection or replication. To overcome the 
problem, stable cell lines should be used and virus control and cell control should be 
included in antiviral assays. 
Appropriate virus titre should be used in antiviral screening assays. Virus 
infectivity assays measure the number of infectious particles in a viral suspension. 
This is done either by plaquing viruses on monolayer cell cultures so as to 
enumerate the number of plaques which originate from a single infectious virus 
particle (plaque forming unit; pfu), or by determining the highest dilution of virus 
suspensions which produce a cytopathic effect (CPE) in 50 % of the inoculated cell 
cultures (50 % tissue culture infectious dose, TCID50). 
Another main concern of antiviral agents is toxicity. In cell culture system, 
cytotoxicity can be assessed by different features of viable or non-viable cells, such 
as the state of metabolic activities. A rapid colorimetric assay for the measurements 
of cell growth and metabolic activity was described in 1983, which was called MTT 
assay (Mosmann, 1983). The assay is based on the reduction of a yellow 
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water-soluble substrate 3-(4,5,-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) which change into a water insoluble blue formazan by the active 
mitochondrial dehydrogenases in living cells, thus the amount of formazan produced 
reflects in proportion to the number of viable cells. The result is found to be reliable 
over a wide range of drug concentrations. 
In the present study, anti-RSV potential of the samples were determined 
by CPE reduction assay. Their cytotoxicity were studied by MTT assay. The 
candidates that inhibited RSV at low concentrations and with low cytotoxicities 
were selected for further study on their modes of antiviral action. 
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2.2 Materials and Methods 
2.2.1 Medicinal plants and phytochemicals 
Dried and chopped samples of A. chinensis, A. pilulifera, A. rubella, P. 
aureocauda, P. odoratum and S. serissoides were obtained from the specialized 
herbal shop in Guangzhou, China. Fresh A. lappa root and P. amaryllifolius were 
purchased from local stores in Hong Kong. Various fractions of P. aureocauda and 
W. indica, as well as a purified compound from W. indica, designated as daphnoretin, 
were kindly provided by Ms. J.Y. Xue of the Department of Chemistry, Jinan 
University, Guangzhou, China. Voucher specimens were deposited in the 
Department of Biology, the Chinese University of Hong Kong, Shatin, Hong Kong, 
China. 
Ribavirin, morin, baicalein, luteolin and gallic acid were purchased from 
Sigma. Naringin was purchased from Fluka and quercetin was purchased from 
Indofine Chemical Company Limited. Cinnamic acid was kindly provided by 
Professor Y.L. Li of the Institute of Traditional Chinese Medicine & Natural 
Products, Jinan University, Guangzhou, China. The purified lectin from the bulbs of 
Narcissus tazetta var. chinensis, designated as NTL, was kindly provided by Dr. 
Linda S.M. Ooi of the Department of Biology, the Chinese University of Hong 
Kong, Shatin, Hong Kong, China. 
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2.2.2 Plant extracts preparation 
2.2.2.1 Aqueous extracts 
For A. pilulifera, 200 g of samples were decocted in 2 L of distilled water 
for 1 h. For A. chinensis, A. rubella, P. aureocauda, S. serissoides, 20 g of samples 
were decocted in 200 ml of distilled water for 1 h. For P. odoratum, 50 g of samples 
were boiled in 300 ml of distilled water for 1 h. For the fresh A. lappa root and P. 
amaryllifolius, the plants were washed, air-dried and chopped into small pieces. 75 g 
of each sample were subsequently boiled in 200 ml distilled water for 1 h. The 
decoctions were then filtered with filter papers and the residues were decocted again. 
The aqueous extracts from two successive extractions were collected, combined and 
concentrated in vacuo at 60 and then lyophilized as crude aqueous extracts. 
2.2.2.2 Ethanol extracts 
Except P. aureocauda and W. indica, ethanol extracts of the plants were 
prepared with the same procedures as those for aqueous extracts except that 95 % 
ethanol were used instead of distilled water. The samples were boiled in a reflux 
system at 50 - 60 using round bottom flasks and heating mantle. The extracts 
were concentrated at 40 - 50 in vacuo. Ethanol crude extracts and solvent 
fractions of P. aureocauda and W. indica were prepared with the assistance of Ms. 
J.Y. Xue (Xue, 2007). Briefly, 10 kg of each plant were immersed in 95 % ethanol 3 
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times, each for 15 days. The extracts were collected, concentrated in vacuo and 
lyophilized. To prepare solvent fractions, 1 kg of dried ethanol extract was dissolved 
in 3 L distilled water and partitioned sequentially with petroleum ether (3 L x 4 
times), ethyl acetate (3 L x 4 times), and butanol (3 L x 4 times). The residue left 
after butanol partition was the residue water fraction. Different fractions were 
collected, concentrated and dried, respectively. 
2.2.3 Cell and virus 
HEp-2 cell (Human larynx epidermoid carcinoma cell line) and RSV 
(Long strain) were purchased from the American Type Culture Collection (ATCC). 
The cells were cultured in the growth medium comprised Eagle's minimum essential 
medium (EMEM, Invitrogen) supplemented with 1.5 g/L sodium bicarbonate, 1 mM 
sodium pyruvate, 24 mg gentamycin sulphate, 0.29 g glutamine (all from Sigma) 
and 10 0/0 fetal bovine serum (FBS, Hyclone) and the cells were incubated at 37 °C 
in a humidified 5 % CO2 atmosphere. 
For RSV culture, 1.75 x lO"^  HEp-2 cells in 100 growth medium were 
seeded into each well of 96-well tissue culture plate and incubated for 24 h. After 
removing the growth medium, RSV stock was diluted using EMEM supplemented 
with 1 0/0 FBS (maintenance medium) and added to the subconfluent HEp-2 cells 
(100 |il/well). The plate was observed daily under microscope for any cytopathic 
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effect (CPE) induced by the virus. When maximal syncytia formation was observed, 
the supernatant was collected and centrifuged at 4 2000 g for 10 min to remove 
cell debris. Aliquots of the supernatant were frozen at -80 until use. 
2.2.4 Endpoint titration of RSV infectivity 
Titration of virus infectivity was performed with a 50% tissue culture 
infectious dose (TCID50) method. HEp-2 cells were seeded in 96-well plate (2.5 x 
104 cells/well) and cultured with the growth medium (100 |il/well) for 24 h at 3 7 � C 
in 5% CO2. When the cells became almost confluent in each well, the medium was 
aspirated and then 100 [i\ of virus suspension at each dilution after serial 10-fold 
dilution using the maintenance medium was added. The virus-inoculated cell 
cultures were further incubated for 4-6 days and CPE of virus were observed daily 
under microscope. The TCID50 value was calculated by the Reed and Muench 
formula (Reed & Muench, 1938), which reflects the dose of virus that produce a 
cytopathic effect in 50% of the cultures inoculated. 
2.2.5 Cytotoxicity test 
Various ethanol extracts, ribavirin, phytochemicals, P. aureocauda and W. 
indica fractions were dissolved in dimethyl sulfoxide (DMSO) to make the stocks 
(40 - 160 mg/ml). They were diluted to appropriate test concentrations with the 
growth medium to make final DMSO concentration not to exceed 0.5%. Aqueous 
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extracts were dissolved in distilled water and filtered through 0.22 |im syringe filters 
to make the stocks (40 mg/ml) and subsequently diluted to test concentrations with 
the growth medium. 
For cytotoxicity test, 0.625 x 10^ HEp-2 cells were seeded in 96-well 
plates and cultured with 100 of growth medium for 24 h at 37 °C in 5% CO2. 
Then 100 |il of two-fold diluted samples were added to the treatment wells. For each 
cell control well, 100 |il of the growth medium without the sample were added. The 
plates were further incubated for 48 h. The medium in each well was removed and 
then 100 |li1 growth medium and 10 jul MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma) at 5 mg/ml 
in phosphate-buffered saline (PBS) were added to each well. The plates were 
incubated for 4 h for the formation of blue formazan. After removing the supernatant, 
the blue formazan were solubilized by adding 100 fil DMSO and the optical density 
(OD) was measured at 570 nm with a microplate reader. The cytotoxic effects of 
different samples on the HEp-2 cells were expressed as percentage inhibition on cell 
metabolic activity and viability, which was calculated by the following equation: 
f , Average OD of treatment w e l l s � 
1 -—; X 100 % 
� Average OD of control wells J 
The percentage inhibition calculated was plotted against the corresponding 
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concentration of sample tested. The concentration of sample with half maximal 
inhibition on the growth and survival of HEp-2 cells (CC50) was analyzed by the 
GraphPad Prism 4.0 software. 
2.2.6 Antiviral assay 
CPE reduction assay was adopted for screening the antiviral activities of 
different samples in this study. Samples were serially two-fold diluted with the 
maintenance medium. In brief, 2.5 x lO"^  HEp-2 cells in 100 growth medium were 
seeded into each well of 96-well plates and incubated for 24 h. When the cells were 
confluent, the growth medium was removed and 100 |li1 of RSV suspension at 100 
T C I D 5 0 and 1 0 0 diluted samples (both in maintenance medium) were added 
simultaneously to the treatment wells. For the virus control wells, RSV and the 
maintenance medium without the sample were added. For the cell control wells, 200 
of the maintenance medium without the sample were added. The plates were 
incubated for 4-6 days for CPE development and CPE in each wells were then 
observed and scored. The percentage of cells showing CPE was scored and 
expressed as follow: no CPE = -; 1-25 % = 1+; 26-50 % = 2+; 51-75 % = 3+; 76-100 
0/0 = 4+. The concentration that reduced 50 % of CPE in respect to virus control was 
defined as 50 % inhibition concentration (IC50) for this assay. The selective index 
(SI) was calculated from the ratio CC50/ IC50 (Cos et al, 2006). 
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2.3 Results 
The extracts from 9 medicinal plants and 9 phytochemicals were studied 
for their inhibition on RSV-induced cytopathic effects (Table 2.1). Some of them did 
not show any inhibitory effects, including aqueous extracts of A. lappa, A. chinensis, 
P. amaryllifolius, P. aureocauda, P. odoratum and S. serissoides, as well as ethanol 
extracts of A. lappa, P. amaryllifolius and P. odoratum. Many of them possessed 
slight inhibitory activities, such as the aqueous extract of A. pilulifera, the ethanol 
extract of A. rubella and A. chinensis, the butanol and residue water fractions of P. 
aureocauda, as well as purified phytochemicals such as naringin, morin, gallic acid, 
cinnamic acid and baicalein. 
On the other hand, the aqueous extract of A. rubella, the ethanol extracts 
of P. aureocauda and S. serissoides, the petroleum ether and butanol fractions of W. 
indica possessed moderate anti-RSV CPE activities. Quercetin and luteolin were 
found too cytotoxic, though they inhibited RSV-induced CPE at low concentrations. 
The compounds with potent anti-RSV activities include the ethyl acetate 
fraction of W. indica (IC5o< 3.91 |ug/ml; SI > 64.1), ethanol extract of A. pilulifera 
(IC50 � 1 5 . 6 ^ig/ml; SI > 32.0), daphnoretin (IC50�7.81 |ig/ml; SI = 21.1), and NTL 
(IC5o~3.13 |ig/ml; SI = 104). The positive control drug ribavirin has an IC50 value of 
about 3.05 fig/ml (Figure 2.1) and SI value 21.4. 
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Figure 2.1. Microscopic photos showing CPE reduction by the positive control 
drug ribavirin in RSV-infected HEp-2 cells (magnification: lOOx). 
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2.4 Discussion 
In this study, CPE reduction assay was employed in the screening of the 
anti-RSV activity of medicinal plant constituents. Though this method is relatively 
qualitative and it is difficult to determine the exact percentage of inhibition at each 
tested concentration, it could still provide information about whether or not test 
compounds at a particular concentration could inhibit RSV-induced syncytium 
formation in a less expensive, less labour intensive and high throughput condition as 
compared to the other screening methods. The test concentrations that could almost 
inhibit 50 % syncytium formation compared to that of the virus control (i.e. close to 
the IC50 value) could then be estimated. Among the extracts or fractions from the 9 
medicinal plant studied, the ethanol extract of A. pilulifera and the ethyl acetate 
fraction of W. indica possess the greatest anti-RSV activity with IC50 values of about 
15.6 |ag/ml and less than 3.91 fig/ml, respectively. Moreover, daphnoretin, the 
purified dicoumarin from the ethyl acetate fraction of W. indica, also exhibits 
antiviral activity with IC50 value of about 7.81 |ig/ml and the compound may 
contribute to the anti-RSV action of the ethyl acetate fraction of W. indica. 
On the other hand, a purified plant lectin, five commercially available 
plant flavonoids and two well-known phytochemicals were also studied for their 
anti-RSV activity. NTL, a lectin isolated from the bulb of N. tazetta, potently 
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inhibited RSV with IC50 value of about 3.13 |ig/ml and with low cytotoxicity (CC50 
=325 |ag/ml). For the other phytochemicals, only baicalein, quercetin and luteolin 
possess anti-RSV activities at relatively lower concentrations. Baicalein was 
previously isolated from Scutellaria baicalensis (Ma et al, 2002) and assessed for 
its anti-RSV activity with IC50 value of 20.8 |Lig/ml and CC50 value of 250 ^ig/ml, but 
the commercially available baicalein used in this study has a higher cytotoxicity. 
This may be due to the difference of chemical source or assay method used, as a 
confluent cell culture was used in the previous study while a growing cell culture 
was employed in this study. Quercetin was reported to inhibit both the infection and 
replication of RSV (Kaul et al, 1985), but there is no information about its 
cytotoxicity. In the present study, baicalein, quercetin and luteolin were found 
relatively toxic at low concentrations, so they were not considered as good 
candidates as antiviral drugs. 
Daphnoretin, NTL and the ethanol extract of A. pilulifera have in vitro 
anti-RSV activity and low cytotoxicity, with SI values about 21.2, about 104 and 
higher than 32, respectively. Therefore, in the next chapter, the ethanol extract of A. 
pilulifera was further fractionated and the mode of antiviral action of the most active 
fraction, together with daphnoretin, were studied. In Chapter 4, the activity of NTL 
as well as other proteins of N. tazetta were further investigated. 
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Chapter 3 
Mechanistic studies of anti-RSV actions of various fractions of Adina 
pilulifera, and daphnoretin, a purified compound from Wikstroemia 
indica 
3.1 Introduction 
Adina pilulifera is a shrub with small leaves, growing on wet soil. It is used 
for treating dysentery, enteritis, dropsy eczema, ulcers, and helps to disperse stasis and 
swelling (Shi & Min, 2003; Zhu & Min, 2005). 
The chemical compositions of A. pilulifera have been reported in some 
studies (Table 3.1). However, there is still no reports on the bioactivity of the fractions 
and compounds extracted from this plant. In the previous chapter, the ethanol extract 
of A. pilulifera was found to possess inhibitory effect on RSV-induced cytopathic 
effect and low cytotoxicity on HEp-2 cells. Therefore, further fractionation of the 
extract was performed and the active fraction was tested for its mode of anti-RSV 
action in the present study. 
Besides A. pilulifera, the mode of anti-RSV action of daphnoretin, which 
was isolated from Wikstroemia indica, was also studied. 
Daphnoretin (7-hydroxyl-6-methoxy-3',7'-dicoumarylether) was first 
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isolated from W. indica in 1979 (Kato et al., 1979). It was found to possess antifungal 
activity by inducing morphological deformation of Pyricularia oryzae mycelia with 
minimum morphological deformation concentration values of 68.4 土 1.3 |aM (Hu et 
al., 2000). The compound caused 97 % inhibition of growth of Ehrlich ascites 
carcinoma cells in an in vivo assay (Lee et al., 1981). Daphnoretin significantly 
inhibits some major sites in the DNA synthetic pathway, such as dihydrofolate 
reductase, orotidine monophosphate decarboxylase, thymidylate monophosphate 
kinase, and ribonucleotide reductase. Reduction of in vitro oxidative phosphorylation 
processes and inhibition of acid hydrolytic enzymes are also observed in the presence 
of daphnoretin (Hall et al., 1982). 
Daphnoretin also possesses the characteristic as an protein kinase C (PKC) 
activator (Ko et al., 1993). It induces respiratory burst in rat neutrophils that may be 
resulted from direct activation of PKC (Wang et al., 1995). Respiratory burst of 
activated neutrophils leads to the productions of reactive oxygen species, which are 
generally believed to be responsible for the antimicrobial effect of neutrophils. 
Furthermore, daphnoretin shows strong suppressive effect on hepatitis B surface 
antigen (HBsAg) expression in human hepatoma Hep3B cells and induces 
translocation of PKC from the cytosol to the membrane and down-regulates 
intracellular PKC levels. It is thus suggested that daphnoretin exerts its antiviral effect 
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similarly to a phorbol ester in regulating gene expression of HBsAg on Hep3B cells 
through the PKC pathway (Chen et al., 1996). 
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(Table 3.1 continued) 
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3.2 Materials and Methods 
3.2.1 Fractionation of A pilulifera ethanol extract 
Ethanol extract of A. pilulifera was prepared by the procedure as described 
in Section 2.2.2.2. The ethanol extract (31.53g) was dissolved in 50 ml distilled water. 
An equal volume of petroleum ether was then added and mixed vigorously. After 
mixing, the mixture was left undisturbed until two layers of solvent were formed. The 
petroleum ether layer was collected and fresh petroleum ether was added with the 
extraction procedure repeated four times until no color is observed in the solvent layer. 
All the collected solvents were pooled and evaporated to form the petroleum ether 
fraction. The aqueous layer was partitioned sequentially with ethyl acetate and 
butanol with the same procedure. The aqueous layer left after the partition became the 
residue water fraction. Different fractions were collected, concentrated and 
freeze-dried. 
3.2.2 Cell and virus 
The method of HEp-2 cells and RSV culture were described in Section 
2.2.3. 
3.2.3 Cytotoxicity test 
Cytotoxicity of the four fractions on growing HEp-2 cells was determined 
by MTT assay. Different fractions were dissolved in DMSO to make the stocks of 160 
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mg/ml and detail procedure was described in Section 2.2.5. 
3.2.4 Endpoint titration of RSV by TCID50 method 
RSV titre was scored by TCID50 determination as described in Section 
2.2.4. 
3.2.5 Antiviral study by CPE reduction assay 
Different fractions were dissolved in DMSO to make the stocks of 80 
mg/ml. RSV at 100 TCID50 and serially two-fold diluted samples were added to 
HEp-2 cells, CPE were observed under a microscope daily. Detail procedure was 
described in Section 2.2.6. 
3.2.6 Endpoint titration of RSV by plaque assay 
HEp-2 cells were cultured with the growth medium in 12-well plate at 37 
in a humidified 5 % CO2 atmosphere for 24 h (3 x 10^ cells/well). When confluent cell 
monolayers were formed, the growth medium was removed and RSV suspension at 
each of the serial ten-fold dilutions using maintenance medium was added to the cells 
(200 i^l/well). The plate was then re-incubated for 2 h with intermittent shaking at 15 
min intervals. After that RSV suspensions were removed and the wells were rinsed 
twice with PBS (1 ml/well) to remove unbound RSV. Then the cells were overlaid 
with 1 0/0 agarose (Invitrogen) in the maintenance medium (1 ml/well). After the 
agarose solidified, a further 1 ml maintenance medium was added. The plate was 
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incubated for 3 days for plaque formation, followed by fixation of cells with 10 % 
formalin and stained with 1 % crystal violet. The number of plaques was counted 
under light microscope after air-drying of the plate. The titre of RSV was expressed as 
the number of plaque forming units per ml (pfu/ml). 
3.2.7 Antiviral study by plaque reduction assay 
The ethyl acetate fraction of A. pilulifera, together with daphnoretin, were 
studied for their half maximal inhibitory concentrations on RSV-induced plaque 
formation. Ribavirin was used as the positive control drug. The three samples were 
dissolved in DMSO to make 80 mg/ml stocks. HEp-2 cells were seeded in 12-well 
plates (3 X 10^ cells/well) and incubated for 24 h. After removing the growth medium, 
100 i^l of RSV at about 80 pfu and 100 t^l two-fold diluted samples (both in the 
maintenance medium) were added to each well. For the virus control wells, 200 |li1 
RSV at final 80 pfu were added. The plates were further incubated for 2 h with 
intermittent shaking. After that, RSV and the samples were discarded and the cells 
were rinsed with PBS twice. The cells were overlaid with 1 % agarose in the 
maintenance medium (1 ml/well). After the agarose solidified, 1 ml sample or 1 ml 
maintenance medium was added to the corresponding wells and virus control wells 
respectively. The plates were then incubated for 3 days to allow the formation of 
plaques. Cells were fixed and stained, and the number of plaques were counted under 
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light microscope. The percentage of inhibition of RSV plaques by the samples were 
calculated by: 
\ A v e r a g e no. o f p laques in t reatment w e l l s ) 
1 X 100 % 
A v e r a g e no. o f p laques in virus control w e l l s J 
The percentage of inhibition calculated were plotted against the 
corresponding concentration of samples and analyzed by the GraphPad Prism 4.0 
software. The half maximal inhibitory concentration on RSV-induced plaque 
formation by each sample was defined as the IC50 for this assay. 
3.2.8 Mode of antiviral action study 
The ethyl acetate fraction of A. pilulifera, daphnoretin, ribavirin, and RSV 
were added to HEp-2 cells with different time of addition, as described in Zhu et al., 
2006, so the samples were present under different conditions: 1) during the early 
infection phase (the first 2 h post-infection) only; 2) during the whole infection phase 
(samples present throughout the experiment), or 3) during the later infection phase 
only (samples only present after 2 h of infection). HEp-2 cells at 3 x 10^ cells/well 
were seeded in 12-well plates and incubated for 24 h. After removing the growth 
medium, 100 |li1 of RSV at about 80 pfu and 100 |ul samples were added to each well 
with a final concentration of 7.81 fig/ml for ethyl acetate fraction and daphnoretin, 
and 3.9 [ig/m\ for ribavirin. For virus control wells and the wells of condition 3, 200 
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1^ 1 RSV at final 80 pfu were added. After further incubation for 2 hours, unbound RSV 
and samples were washed away by rinsing the cells with PBS twice. The cells were 
overlaid with 1 % agarose in the maintenance medium (1 ml/well). After the agarose 
solidified, 1 ml of sample at double concentration (15.625 |Lig/ml for ethyl acetate 
fraction and daphnoretin, and 7.81 |Lig/ml for ribavirin) was added to each well of 
conditions 2 and 3. For each of the virus control wells and the wells of condition 1, 1 
ml maintenance medium was added. After plaque development, the number of 
plaques was counted and the percentage of plaques formed under different conditions 
compared to the virus control were calculated by: 
, A v e r a g e n o . o f p l a q u e s in t r e a t m e n t w e l l s ) 
X 1 UU / 0 
� A v e r a g e n o . o f p l a q u e s in v i rus c o n t r o l w e l l s J 
The results were analyzed with one-way ANOVA followed by Tukey's multiple 
comparison test by the GraphPad Prism 4.0 software. 
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3.3 Results 
A. pilulifera ethanol extract (31.5 g) was first partitioned with different 
organic solvents from low to high polarity. The fractions were concentrated and dried, 
and about 2.40 g petroleum ether fraction, 3.27 g ethyl acetate fraction, 11.1 g butanol 
fraction, and 8.28 g residue water fraction were obtained, respectively. The fractions 
were tested for their anti-RSV activity by CPE assay and their cytotoxicity were 
tested by MTT assay. Except the residue water fraction, the other three fractions 
possess anti-RSV activity with IC50 values of about 7.81, < 7.81 and 31.3 |ig/ml for 
the petroleum ether, ethyl acetate and butanol fraction respectively. However, the 
petroleum ether fraction was also found cytotoxic with CC50 value of 122 |ig/ml and 
among the three fractions, the ethyl acetate fraction has the highest SI value (Figure 
3.1). Therefore, this fraction was chosen for further study. 
In the next study, the IC50 values of ribavirin, daphnoretin and the ethyl 
acetate fraction of A. pilulifera were determined by plaque reduction assay, which 
were 2.18, 5.87 and 2.22 |ig/ml respectively. Their SI values, calculated with the IC50 
values determined by plaque reduction assay, were 30.0, 28.2 and 86.2 respectively 
(Table 3.2). 
Their modes of antiviral action were studied by the addition of samples 
during different phases of the virus infection cycle. Significant reductions on plaque 
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formation were observed when the three samples were present during the whole 
infection cycle. Also, for ribavirin and the ethyl acetate fraction, similarly significant 
reduction on plaque number were also observed when the drug was only present 
during the later infection phase. For daphnoretin, a slight inhibitory effect was 
observed when the sample was only present during the early infection phase, while a 
more significant inhibition was observed when the sample was only added during the 
later infection phase (Figure 3.2). 
- 7 1 -
Chapter 3 Mechanis t ic studies o f A d i n a p i l u l i f e r a fraction and daphnoretin 
Table 3.2 CC50, IC50 and SI of ribavirin, daphnoretin and A. pilulifera ethyl 
acetate fraction. 
CC50 杯 IC5Q SI 
(叩/ml) (\ig/m\) 
Ribavirin* 65.2 2.18 30.0 
Daphnoretin 165 5.87 28.2 
Ethyl acetate fraction of A. pilulifera 191 2.22 86.2 
1) #: IC50 - concentration that leads to half maximal inhibition on number of 
plaques compared to virus control 
2) SI: selectivity index (CC50/IC50) 
3) CC50 and IC50 were calculated from data obtained from three independent 
experiments with the generation of dose-response curves by GraphPad 
Prism 4.0 software. 
4) Ribavirin is the positive control drug. 
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200 g A, pilulifera 
95 % ethanol extraction 
\ Concentration in vacuum 
31.5 g crude ethanol extract 
IC50 = 15.6 | ig/ml 
CC50 = >500 |ug/ml 
SI = > 3 2 
Partition in water and organic solvents 
1 r 
• + + + 
Petroleum ether Ethyl acetate Butanol Residue water 
fraction fraction fraction fraction 
(2.4 Ig) (3.27g) (11.Ig) (8.28g) 
IC50 = 7.81|Lig/ml IC50 = <7.81|Lig/ml IC50 = 31.3^ig/ml IC50 = 125^g/ml 
CC50 = 122 | ig /ml CC50= 191^g/ml CC50 = > 2 5 0 ^ g / m l CC50 = >250^g /ml 
SI = 1 5 . 6 SI = >35 .8 SI = >8 SI = � 2 
Figure 3.1 Fractionation of A,pilullfera, 
The values of IC50 refer to the concentrations nearest to the actual IC50 
(i.e. 50 0/0 reduction of cytopathic effect in respect to virus control in 
CPE assay). 
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A Ribavirin 
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2 ^ ^ ^ ^ condition 1: early infection phase only 
o 75- condition 2: whole infection phase 
^ w ^ ^ f f i condition 3: later infection phase only 
i i l m 






o 75 - p ^ ^ m w condition 1: early infection phase only 
(/) 籍齋靈 condition 2: whole infection phase 
> feKwS condition 3: later infection phase only 
！ llL 
vc 1 2 3 
Condition 
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Figure 3.2 Mode of antiviral action study by plaque reduction assay. 
HEp-2 cells were infected by RSV at about 80 pfu and A) 3.9 |ig/ml 
ribavirin, B) 7.81 )ig/ml daphnoretin, or C) 7.81 jig/ml ethyl acetate 
fraction of A. pilulifera were added during the early infection phase 
only (i.e. the first 2 h only), during the whole infection phase (i.e. 
samples present throughout the experiment), or during the later 
infection phase only (i.e. after the first 2 h). The percentage of number 
of plaques formed under different conditions compared to the virus 
control (VC) were calculated and analyzed by one-way ANOVA 
followed by Tukey's multiple comparison post-test, P<0.001. In each 
graph, the bars marked by the same letter have no significant 
difference. Results were expressed as mean 士 S.D. obtained from three 
to four independent experiments with duplicate wells for each 
condition. 
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3.4 Discussion 
Compounds with different polarities can be separated by fractionation of the 
ethanol extract of A. pilulifera using different organic solvents from low to high 
polarity, and the fractions showed different degree of inhibition on RSV. The residue 
water fraction, though not highly cytotoxic, could only inhibit RSV at a relatively 
high concentration (IC50 �125 iig/ml). The other three fractions possess better 
inhibitory effect on RSV-induced CPE with the petroleum ether fraction being the 
most cytotoxic (CCso^ 122 |ig/ml). The SI values of the ethyl acetate fraction (>35.8) 
was comparable to that of the ethanol extract (>32), while the other two fractions have 
lower SI values. Therefore, more in-depth studies of the ethyl acetate fraction, 
together with daphnoretin and ribavirin, were carried out. First, their IC50 values were 
studied with plaque reduction assay. This assay is quantitative, and the number of 
plaques formed reflects the number of infectious virions present. However, the assay 
is rather labour intensive, thus it is not suitable for high-throughput screening. The 
IC50 values obtained were used for calculation of the SI values, and it was found that 
SI value of daphnoretin was comparable to that of ribavirin (28.2 and 30.0 
respectively) while the ethyl acetate fraction had a much higher SI value (SI = 86.2) 
than both ribavirin and the original ethanol extract. 
Second, in order to determine which stage(s) of the RSV replication cycle 
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was inhibited by these samples (i.e. their modes of action), time-of-addition studies 
were carried out. The growth kinetics of RSV in cell cultures were studied in the 
1960s, which found that the virus required 1 to 2 hours for adsorption and penetration, 
and viral antigen appears in the cytoplasm 9 to 10 hours after infection. At 10 to 14 
hours, the first mature virus appears, and the virus growth cycle in HEp-2 cells is 45 -
50 hours (Bennett & Hamre, 1962; Jordan, 1962; Kisch et al., 1962; Levine & 
Hamilton, 1969). It was also reported that approximately 60-90 % of RSV adsorb to 
cells in 30 minutes at 37 and over 95 % by 10-12 hours. Adsorbed viruses 
penetrate the cells within 45 minutes through virus-cell fusion (Levine & Hamilton, 
1969; Stott & Taylor, 1985). Therefore, in usual RSV assays, the time allowed for 
virus adsorption and fusion is about 2 hours post-infection. In our time-of-addition 
studies, the test samples were either present for only 2 hours (condition 1: during the 
early infection phase only), present during the whole time course of plaque reduction 
assay (condition 2: during the whole infection phase), or present only after the first 2 
hours of infection (condition 3: the later infection phase only). In order to achieve a 
more apparent difference between condition 2 and the virus control, concentrations of 
the test samples added (3.9 |ig/ml for ribavirin; 7.81 |ig/ml for both daphnoretin and 
the ethyl acetate fraction) were greater than their IC50 values. The results showed that 
for ribavirin and the A. pilulifera ethyl acetate fraction, no significant reductions on 
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plaque numbers were observed when the samples were present only in the early 
infection phase. On the other hand, significant decreases in the number of plaques 
were observed even when the samples were added after viral attachment and fusion. 
The decreases were comparable to that when the samples were present throughout the 
whole RSV infection cycle. The result of ribavirin was similar to that reported 
previously (Hruska et al., 1980), which stated that ribavirin was still able to inhibit 
RSV plaque formation when added as late as 12 hours post-infection. Although the 
actual underlying mechanism of its inhibitory effect is still unknown, the actions and 
mechanisms of ribavirin on other viruses were reported, including the reduction of 
intracellular guano sine triphosphate pools, inhibition of capping of viral transcripts or 
suppression of humoral and cellular immune responses (Leyssen et al., 2008). The 
result of the ethyl acetate fraction of A. pilulifera indicated that its mode of action is 
not likely by inhibition of viral attachment or fusion, but by inhibition of the later 
events of the virus replication cycle (such as replication, viral assembly or viral 
release) or by modulation of host cell's biological events to achieve the antiviral 
purpose. 
For daphnoretin, about 25 % reduction in number of plaque was observed 
when the compound was present during the early infection phase only, and about 80 
o/o reduction was observed when the compound was added after viral attachment and 
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fusion (i.e. 2 h post-infection), which showed a similar level of reduction as that when 
the compound was always present. Thus daphnoretin might be able to slightly inhibit 
viral attachment and/or fusion, and mainly inhibit the later viral development and 
spreading. Daphnoretin was reported as a PKC activator (Ko et al., 1993; Wang et al, 
1995; Chen et al, 1996). PKC is a large superfamily of calcium and 
phospholipids-dependent serine/threonine kinases with many isotypes. PKC has been 
implicated in the control of various cellular signals required for activation, 
proliferation, differentiation and survival. Upon stimulation and activation, 
translocations of PKC from cytosol to plasma membrane or other subcellular 
compartments occur. Different physiological stimuli induce selective translocation of 
PKC isotypes to distinct subcellular compartments (Shirai & Saito, 2002). It was 
found that P K C is involved in the RSV-induced nuclear factor kappa B ( N F - K B ; 
cellular transcription factor) and extracellular signal-related kinase (ERK) activation, 
which are involved in the release of the inflammatory mediator interleukin 8 and 15 
(Bitko & Barik, 1998; Monick et al., 2001; Ennaciri et al., 2007) and hence immune 
response elicitation. Interestingly, the activation and translocation of one of the PKC 
isotype, PKCa, to cell membrane was observed upon RSV contact and to facilitate 
RSV fusion (San-Juan-Vergara et al, 2004). Other PKC isotypes are not involved and 
the translocated PKCa were found colocalized with the attached RSV on plasma 
- 7 9 - • 
Chapter 3 Mechanistic studies o f Adina pilulifera fraction and daphnoretin 
membrane. However, it is unknown how PKCa is activated and how activated PKC 
facilitates RSV fusion, although it is speculated that there may be a relationship 
between PKCa-related caveolae formation and RSV-caveola binding. 
On the other hand, daphnoretin activates PKC by direct binding to its 
regulatory domain, induces its translocation to the plasma membrane and lead to 
down-regulation of intracellular PKC level (Wang et al, 1995; Chen et al, 1996), 
although the isotype of PKC involved was not mentioned. It is unknown whether the 
inhibition of RSV plaque formation by daphnoretin in our study is related to its PKC 
activator role. But as the early infection phase of RSV is slightly inhibited by 
daphnoretin, it might be related to the reduction of the intracellular PKC pool by 
daphnoretin and thus less PKC were available for RSV-induced activation and 
translocation, thus affected RSV fusion. Daphnoretin is also able to inhibit RSV at the 
later infection phase, which may be due to direct inhibition on RSV replication 
process or modulation of cellular events in the host cell that interfere other events of 
the RSV replication cycle. 
In next chapter, the antiviral activity of Narcissus tazetta proteins and the 
mode of antiviral action of the most potent protein were studied. 
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Chapter 4 
Antiviral activity of Narcissus tazetta proteins 
4.1 Introduction 
Many plant proteins have antiviral activities against human viruses. For 
example, meliacine isolated from Melia azedarach is able to inhibit HSV-1 in vitro 
and in vivo by inhibiting specific infected-cell polypeptides produced in later phase 
in the virus infection cycle. Some of these polypeptides are involved in DNA 
synthesis and in the assembly of nucleocapsids, thus the production of viral DNA 
and maturation of the virus are affected (Alche et al, 2002). A xylanase isolated 
from the roots of Panax notoginseng has suppressive effect on HIV-1 reverse 
transcriptase (Lam & Ng, 2002). 
Besides, some ribosome-inactivating proteins (RIPs), such as pokeweed 
antiviral protein (PAP) from Phytolacca americana, trichosanthin from 
Trichosanthes kirilowii, MAP30 and MRK29 from Momordica charantia, as well as 
GAP31 from Gelonium multiflorum, are able to inhibit different viruses 
(Chattopadhyay & Naik, 2007). PAP can inhibit human cytomegalovirus (HCMV), 
HSV, HIV and influenza virus by specific depurination of both adenines and 
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guanines from viral and ribosomal RNA, and it also causes damage to the viral 
nucleic acid (Parikh & Turner, 2004). Trichosanthin is able to inhibit HIV with other 
mechanism independent of ribosome inactivation. It also possesses anti-HSV 
activity, and this activity is substantially potentiated when it is used together with 
acyclovir or interferon (Zheng et al, 2001). MAP30 and GAP31 inhibit the action of 
HIV-1 integrase, and also inhibit supercoil of HIV-1 DNA (Lee-Huang et al, 1995). 
The two RIPs also inhibit HSV (Bourinbaiar & Lee-Huang, 1996). Furthermore, 
crude MRK29 causes 50 % inhibition on HIV-1 reverse transcriptase, and partially 
purified MRK29 is able to cause 82 % inhibition of HIV-1 p24 production in 
infected cells (Jiratchariyakul et al, 2001). 
Another group of antiviral proteins is plant lectins. Lectins are 
carbohydrate-binding proteins of non-immune origin that specifically bind to 
different carbohydrates without biochemical modification of their substrates. They 
are found in microorganisms, plants and animals. Among them, plant lectins have 
been detected in more than a thousand species of plants and several hundreds have 
been isolated. They are different in molecular structures and biochemical properties, 
and have been found in various vegetative tissues, and their levels in these tissues 
are variable and exhibit seasonal changes (Peumans & Van Damme, 1995). Some of 
the plant lectins and their carbohydrate specificities are listed in Table 4.1. 
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Table 4.1 Examples of plant lectins. 
Plant Lectin abbreviation Carbohydrate specificity 
Orchidaceae 
Lister a ovata LOA a(l,3)Man 
Epipactis helleborine EHA Man 
Cymbidium hybrid CHA Man 
Amaryllidaceae 
Galanthus nivalis GNA a(l,3)Man 
Hippeastrum hybrid HHA a(l,3)-a(l,6)Man 
Narcissus pseudonarcissus NPA a(l,6)Man 
Alliaceae 
Allium porrum APA Man 
Allium ursinum AUA Man 
Pandanaceae 
Pandanus amaryllifolius Pandanin Man 
Moraceae 
Artocarpus integhfolia Jacalin Gala(l ,6)/Galp(l ,3)GalNAc 
Fabaceae 
Canavalia ensiformis ConA Man>Glc>GlcNAc 
Pisum sativum PSA Man�Glc/GlcNAc 
Lens culinahs LCA Man>Glc>GlcNAc 
Viciafaha VFA Man>Glc/GlcNAc 
Lathyrus odoratus - Man>Glc>GlcNAc 
Urticaceae 
Urtica dioica UDA GlcNAc oligomers 
Cecropiaceae 
Myrianthus holstii MHA GlcNAc 
Euphorbiaceae 
Hevea brasiliensis HBA GlcNAc 
Gal: galactose; GalNAc: N-acetylgalactosamine; Glc: glucose; GlcNAc: 
N-acetylglucosamine; Man: mannose. The > symbol indicates a higher preference. 
(Adapted from Balzarini, 2007a). 
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Plant lectins play important biological roles both within and outside the 
plant. In leguminous plants, lectin may involve in symbiosis between nitrogen-fixing 
bacteria and the plants. In many other plants, lectins are usually associated with 
storage tissues such as seeds, tubers, bulbs, corms, rhizomes, root stocks and bark. 
Many of these lectins have been shown to also exhibit behaviour similar to other 
storage proteins. Their biosynthesis, subcellular localization, and developmental 
regulation are similar to other storage proteins. During seed germination or depletion 
of vegetative tissues during growth, lectins are degraded and appear to be important 
sources of nitrogen for the development process (Komath et al, 2006). 
Besides, a majority of plant lectins are involved in defense. Plants have to 
rely on constitutive or inducible accumulation of toxic low molecular weight 
secondary metabolites or proteins as defense strategies. These toxins may possess 
broad spectrum or specific activities. Lectins are capable to recognize and 
specifically bind to glycoconjugates present on the external surface of 
microorganisms, such as chitin in the fungal cell wall, or on the luminal surface of 
the gastrointestinal tract of plant predators like insects and animals. Some extremely 
cytotoxic proteins such as ricin, abrin and modecin are non-selective toxin for all 
eukaryotic organisms. These toxins inactivate all eukaryotic ribosomes by cleavage 
of the jV-glycosidic bond of the 28S rRNA adenosine residue. A lectin of Urtica 
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dioica has potent antifungal properties (Broekaert et al., 1989). It appears to affect 
the synthesis of the fungal cell wall (Van Parijs et al, 1992). Some plant lectins have 
anti-insect properties, for example, the mannose-binding snowdrop {Galanthus 
nivalis) lectin is toxic for some chewing and sucking insects. It is not only active 
when included in an artificial diet for the insects but also when the insects were fed 
with transgenic plants expressing the lectin gene (Hogervorst et al, 2006). The 
antinutritional effect of toxic lectins is not limited to insects, but also to animals and 
human. Oral acute toxicity of lectins on human includes nausea, bloating, vomiting 
and diarrhea. Experimental animals that fed on diet containing these lectins resulted 
in loss of appetite, decreased body weight and eventually death. Toxic plant lectins 
can affect gut epithelial cell turnover, damage the luminal membranes of the 
epithelium, interfere with nutrient adsorption and digestion, stimulate bacterial flora 
shifts and modulate the immune state of the digestive tract (Vasconcelos & Oliveira, 
2004). Consequently, seeds and vegetative tissues that contain such antinutritive 
lectins are unpalatable and will be avoided, and this is beneficial for the plant 
species. 
Lectins have been applied in different aspects of bioscience and 
biomedicine. They are used in detection, isolation and structural studies of 
glycoprotiens. They are also employed for studying membrane structures and the 
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changes of glycoconjugates during cell differentiation, growth and development. 
Moreover, lectins are useful in mapping neuronal pathways, cell identification and 
separation, as well as identification of microorganisms. Clinical uses of lectins 
include blood typing, preparation of chromosome maps, used as mitogens for testing 
of immune state of patients, and purging human bone marrow for transplantation 
(Lis & Sharon, 1998). In recent years, lectins have been tested for their toxicities 
against different cancer cells (Valentiner et al, 2003; Heinrich et al, 2005). 
Mistletoe lectins, for example, inhibit acute lymphoblastic leukemia both in vitro 
and in vivo (Seifert et al, 2008). Some lectins have been used as carriers that are 
conjugated with chemotherapy drugs. The specificity of the lectins helps delivering 
the drugs to target sites (Bies et al, 2004). 
Many lectins possess antiviral properties against human enveloped viruses. 
Glycans on the viral envelope often have a crucial role in the entry of virus into the 
host cell and/or efficient transmission. Antiviral lectins can bind to the glycans of the 
viral envelope glycoproteins, thereby inhibiting the normal functions of the glycans. 
The antiviral activities of various lectins have been demonstrated mainly in HIV 
researches, which were based on different HIV strains and target cell types 
(Balzarini, 2007b). Lectins activities against HCMV, HCV, influenza virus, HSV, 
poxvirus, RSV and SARS-CoV were also published (Ooi et al, 2004; Bertaux et al, 
- 8 6 -
Chapter 4 Antiviral activity o f Narcissus tazetta proteins 
2007; Favacho et al, 2007; Kaur et al, 2007; Keyaerts et al, 2007; Luo et al, 
2007). 
Plant proteins or lectins are indeed potential sources of novel anti-RSV 
agents. In this study, some Narcissus tazetta proteins were assessed for their 
anti-RSV activity. N. tazetta is a monocotyledonous perennial ornamental plant of 
the family Amaryllidaceae. The medicinal plant is used externally for parotitis, 
mastitis, boils and abscesses (Ooi et al., 1998). Active substances, including 
pseudolycorine, lycorine, and tazettine, are present in the extract of N. tazetta var. 
chinensis (Liu et al, 2006). In our laboratory, mannose-binding lectins have been 
isolated from leaves and bulbs of the plant (Ooi et al, 1998; Ooi et al, 2000). In the 
present study, anti-RSV activity of the Narcissus tazetta lectin (NTL) previously 
purified from N. tazetta var. chinensis as well as proteins isolated from another 
cultivar of N. tazetta were examined. 
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4.2 Materials and Methods 
4.2.1 Crude proteins extraction from Narcissus tazetta cultivar 
Bulbs of the N. tazetta cultivar were bought from mainland China. After 
cleaning and removal of roots and dried scale leaves, the bulbs were cut into small 
pieces and homogenized in 0.2 M NaCl. The homogenate was stored in 4 
overnight, which was then centrifuged at 22,095 g for 30 minutes to remove debris. 
Ammonium sulfate at 356 g/L were added to the supernatant to a 80 % saturation. 
The precipitated proteins were collected after centrifugation and dialyzed 
extensively against distilled water to remove the salts. Crude protein powder was 
obtained after freeze-drying of the dialyzed proteins. 
4.2.2 Separation of proteins with affinity column 
The crude protein powder was dissolved in 20 mM MES buffer of pH 6.2 
and fractionated on a D-mannose-agarose (Sigma) column. Unadsorbed proteins (the 
Ml fraction) were eluted with MES buffer, and adsorbed proteins were desorbed 
with MES buffer containing 0.2 M mannose to give the M2 fraction. The M3 
fraction was obtained after washing the column with MES buffer containing 0.5 M 
NaCl. The fractions were desalted and mannose was removed by dialysis and the 
proteins were lyophilized. 
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4.2.3 Gel filtration of protein fractions on Superose column 
Proteins with different molecular mass in the M2 and M3 fractions were 
separated by the Superose 12 HR 10/300 column on the fast protein liquid 
chromatography (FPLC) system (Pharmacia). The column was first calibrated with 
different molecular weight standards including bovine serum albumin (66 kDa), 
ovalbumin (45 kDa), carbonic anhydrase (29 kDa), cytochrome c (12.5 kDa), 
aprotinin (6.5 kDa), and cytidine (246 Da). The M2 or M3 fractions were dissolved 
in 0.1 M ammonium bicarbonate buffer, pH 8.0 and injected into the FPLC system. 
Proteins were eluted with the same buffer at flow rate of 0.4 ml/min and collected at 
0.4 or 0.8 ml/tube, which were then desalted with PD-10 desalting columns (GE 
Healthcare) and lyophilized. 
4.2.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
The protein profiles of crude protein extract and various fractions were 
studied by SDS-PAGE. Proteins were mixed with loading dye (1:1) with 2 % 
sodium dodecyl sulfate (SDS) and 2 % P-mercaptoethanol and denatured for 5 
minutes at 95 A low range SigmaMarker™ (Sigma) and the proteins were then 
resolved using 15 % SDS-polyacrylamide gels. After electrophoresis the gels were 
stained with Coomassie Brilliant Blue R-250 for 1 h and subsequently destained 
with 10 % acetic acid and 40 % methanol. 
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4.2.5 Electroblotting and N-terminal amino acid sequence analysis 
After SDS-PAGE, the proteins on the gel were transferred onto 
polyvinylidene difluoride (PVDF) membrane using Dunn's buffer containing 
sodium carbonate, sodium hydrogencarbonate and SDS. The membrane was then 
stained with Coomassie Brilliant Blue R-250 until blue bands were observed, and 
then destained with methanol. The membrane was air-dried and the desire bands 
were cut out for N-terminal amino acid sequence determination using an HP 
G1000A Edman degradation unit and HP-1000 HPLC system. The amino acid 
sequence analysis was done by Ms. Jessie Lee of the Department of Biology, The 
Chinese University of Hong Kong. 
4.2.6 Protein concentration determination 
Concentrations of proteins were determined by the standard bicinchoninic 
acid assay (BCA) kit (Pierce). A standard curve was prepared using 50 fil of 0, 25, 
50, 100, 200 and 400 |ig/ml bovine serum albumin, and 50 |il of protein samples 
were used for the test. 1ml BCA working reagent, containing 50 parts of reagent A 
and 1 part of reagent B (provided), was then added to each tube and incubated for 30 
minutes at 37 After incubation, all the tubes were cooled to room temperature. 
Absorbance was measured at 562 nm using a BioPhotometer (Eppendorf). Protein 
concentrations of the samples were determined from the standard curve. 
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4.2.7 Isolation and purification of TV. tazetta lectin (NTL) 
NTL was isolated as described in a previous study (Ooi et al, 2000) and 
kindly provided by Dr. Linda Ooi. In brief, after homogenization of the bulbs of N. 
tazetta var. chinensis in 0.2 M NaCl and precipitation with ammonium sulfate at 
30 — 80 % saturation, crude proteins were subjected sequentially to diethylamino 
ethanol-cellulose (Sigma) affinity column, mannose-agarose (Sigma) column, and 
Superose FPLC column (Pharmacia). Purified NTL (the DEAE P2M2GF fraction 
described in Ooi et al, 2000) was obtained after desalting the proteins with PD-10 
and analyzed by SDS-PAGE, and the N-terminal amino acid sequence was also 
determined. Haemagglutination activity of NTL was examined by mixing a serial 
two-fold dilution of the lectin with a 2 % suspension of rabbit erythrocytes in PBS. 
Haemagglutination inhibition tests were performed by mixing different sugar 
samples with NTL before adding rabbit erythrocyte suspension and the minimal 
concentration of the sugar that completely inhibited haemagglutination was 
calculated. The presence of carbohydrates in the lectin was tested by Fuchsin-sulfite 
staining after electrophoresis and electroblotting. The molecular mass of the purified 
NTL was determined to be about 26 kDa by gel filtration and 13 kDa by SDS-PAGE, 
and the NTL is therefore a mannose-binding, non-glycoprotein dimer with a 
molecular subunit of 13 kDa. 
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4.2.8 Antiviral activities of N, tazetta proteins and NTL 
4.2.8.1 Cell and virus 
The method of HEp-2 cells and RSV culture were described in Section 
2.2.3. 
4.2.8.2 Cytotoxicity test 
Cytotoxicities of the proteins on growing HEp-2 cells were determined by 
MTT assay. Different proteins were dissolved in Milli-Q water and filtered through 
0.22 )im syringe filters to make the stocks of 200 |ig/ml and detail procedures were 
described in Section 2.2.5. 
4.2.8.3 Endpoint titration of RSV by TCIDw method 
RSV titre was scored by TCID50 determination as described in Section 
2.2.4. 
4.2.8.4 Antiviral study by CPE reduction assay 
RSV at 100 TCID50 and serially two-fold diluted proteins were added to 
HEp-2 cells and CPE were observed daily. Detail procedures were described in 
Section 2.2.6. 
4.2.8.5 Endpoint titration of RSV by plaque assay 
Detail procedures were described in Section 3.2.6. 
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4.2.8.6 Antiviral study by plaque reduction assay 
RSV plaque reduction was used to determine the IC50 of NTL. Detail 
procedures were described in Section 3.2.7. 
4.2.8.7 Mode of antiviral action study 
NTL at a final concentration of 10 |ig/ml was used for the assay. Detail 
method was described in Section 3.2.8. 
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4.3 Results 
An amount of 1.66 g of crude protein was extracted from 1.25 kg of N. 
tazetta cultivar bulbs (Figure 4.1 C & D). The crude protein was first fractionated 
with mannose-agarose column (Figure 4.2), and adsorbed proteins were eluted with 
buffer that contain 0.2 M mannose (the M2 fraction, 9.92 mg) and subsequently with 
0.5 M NaCl (the M3 fraction, 14.36 mg). 
The two fractions were then subjected to FPLC, and the Superose 12 
FPLC column was calibrated with various molecular weight standards to estimate 
their retention time (Table 4.2) and to generate a standard curve (Figure 4.3). For the 
M2 fraction, its FPLC fractions eluted at about 37.36 minute (an average of 4 
experiments) were collected, pooled and designated as NTM2 (Figure 4.4), which 
has a molecular weight of 15.2 kDa as calculated with the FPLC standard curve. 
SDS-PAGE of NTM2 revealed a prominent band near the 14.2 kDa marker (Figure 
4.7). For the M3 fraction, FPLC fractions eluted at about 40.38 minute (an average 
of 4 experiments) were pooled and designated as NTM3 (Figure 4.5), which is 6.7 
kDa as calculated with the FPLC standard curve and showed a prominent band near 
the 6.5 kDa marker after SDS-PAGE (Figure 4.7). The extraction scheme of the 
proteins was showed in Figure 4.6. 
The N-terminal amino acid sequence of NTM2 and NTM3 were analyzed 
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(Table 4.3). As there were not enough proteins prepared and blotted on membrane, 
only the first 20 and 5 amino acid residues of NTM2 and NTM3 were determined 
respectively. The first 20 N-terminal amino acid sequence of NTM2 shared a 45 % 
homology with that of NTL (Table 4.3), which was isolated from N. tazetta var. 
chinensis (Figure 4.1 A & B). NTL is a mannose-binding, non-glycoprotein dimer 
with a molecular subunit of 13 kDa (Ooi et al., 2000). SDS-PAGE analysis of NTL 
revealed a protein band below the 14.2 kDa marker (Figure 4.7). 
The proteins were tested for their anti-RSV activity by CPE assay and 
their cytotoxicity were tested by MTT assay (Table 4.4). NTM2 and NTM3 showed 
mild anti-RSV activity (IC50 value of about 25 and 50 |ig/ml, respectively) and were 
relatively cytotoxic to HEp-2 cells (CC50 value of about 76.9 and 67.8 jug/ml, 
respectively). On the other hand, NTL inhibited RSV plaque formation (IC50 二 
2.30^ig/ml) and exhibited low cytotoxicity (CC50 = 325 |ig/ml), and has a SI value 
141 (Figure 4.8 & Table 4.5). Therefore, its mode of action was studied. Significant 
reductions on plaque formation were observed when the NTL was present during the 
whole infection cycle. Also, NTL was able to reduce plaque formation when it was 
either only present during the early infection phase or added during the later 
infection phase (Figure 4.9). 
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Table 4.2 Analysis of molecular weight standards by FPLC. 
Molecular weight MW Retention time Relative retention 
standard (kDa) (min) time 
Bovine serum albumin 66.0 30.2 0.586 
Ovalbumin 45.0 33.2 0.643 
Carbonic anhydrase 29.0 35.8 0.693 
Cytochrome c 12.5 38.6 0.747 
Aprotinin 6.50 42.2 0.818 
Cytidine 0.246 ^ LOO 
Table 4.3 Amino acid residues at the N-terminus of NTM2, NTM3 and NTL. 




The N-terminal sequence of NTL was determined by Ooi et al, 2000. Identical 
amino acid residues were underlined. “ ” denoted that the amino acid sequence 
was not analyzed further. 
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Table 4.4 CPE reduction and cytotoxicity of NTM2, NTM3 and NTL. 
Protein Test concentration CC50 (jig/ml) SI^ 
nearest to IC50 (jiig/ml) 
NTM2 25.0 76.9 3.08 
NTM3 50.0 67.8 1.36 
NTL 3.13 325 104 
IC50： 50 % inhibition concentration; concentration that reduced 50 % of cytopathic 
effect in respect to virus control. 
a: Selectivity index calculated based on the ratio of CC50 to the test concentration 
nearest to IC50. 
Table 4.5 IC50, CC50 and SI values of NTL as determined by plaque reduction 
assay. 
IC50'(叩/ml) CC50 (^g/ml) SI 
2.30 325 141 
1) #: IC50 - concentration that leads to half maximal inhibition on number of 
plaques compared to virus control 
2) SI: selectivity index (CC50/IC50). 
3) CC50 and IC50 were calculated from data obtained from three independent 
experiments with the generation of dose-response curves by GraphPad 
Prism 4.0 software. 
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Figure 4.2 Affinity chromatography of TV. tazetta cultivar crude protein extract 
on mannose-agarose column. 
The mannose-agarose column was equilibrated with MES buffer 
(20mM, pH 6.2). The unadsorbed material (Ml) was eluted with the 
same buffer, and the adsorbed proteins were eluted with 0.2M mannose 
in MES (M2) or 0.5M NaCl in MES (M3). The arrows indicate the time 
at which buffer was changed. 
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Figure 4.3 Analysis of molecular weight standards by Superose 12 FPLC 
column. 
Superose 12 HR 10/300 column was equilibrated with O.IM NH4HCO3 
buffer, and calibrated with bovine serum albumin, ovalbumin, carbonic 
anhydrase, cytochrome c, aprotinin and cytidine. Relative retention 
time is the ratio of retention time of different standards to that of 
cytidine. 
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Figure 4.4 Gel filtration of the M2 fraction of N, tazetta cultivar by FPLC. 
The M2 fraction was dissolved in 0.1 M NH4HCO3 and eluted with the 
same buffer at a flow rate 0.4 ml/min. Fractions were collected and 
analyzed by SDS-PAGE and the fractions eluted around the first 
prominent peak (37.31 min) were pooled and designated as NTM2. 
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Figure 4.5 Gel filtration of the M3 fraction of TV. tazetta cultivar by FPLC. 
The M3 fraction was dissolved in 0.1 M NH4HCO3 and eluted with the 
same buffer at a flow rate 0.4 ml/min. Fractions were collected and 
analyzed by SDS-PAGE and the fractions eluted around the highest 
peak (40.5 min) were pooled and designated as NTM3. 
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Figure 4.6 Isolation scheme of K tazetta cultivar protein. 
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Figure 4.7 SDS-PAGE of NTL and TV. tazetta cultivar crude and fractionated 
proteins. 
Proteins were separated on 15 % gel and stained by Coomassie Brilliant 
Blue R-250. M: Low range SigmaMarker'^^. 
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Figure 4.8 Inhibition of RSV plaque formation by NTL. 
Percentage of RSV-plaque inhibition after addition of different 
concentrations of NTL to infected HEp-2 cells were calculated and 
dose-response curve was generated by GraphPad Prism 4.0 software. 
Data were obtained from three independent experiments and expressed 
as mean 士 S.D. 
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Figure 4.9 Mode of anti-RSV action of NTL by plaque reduction assay. 
HEp-2 cells were infected by RSV at about 80 pfu and 10 |Lig/ml NTL 
were added during the early infection phase only (2 h post-infection 
only), during the whole infection phase, or during later infection phase 
only (after 2 h post-infection). The percentage of number of plaques 
formed under different conditions compared to the virus control (VC) 
were calculated and analyzed by one-way ANOVA followed by Tukey's 
multiple comparison post-test, P<0.001. The bars marked by the same 
letter have no significant difference. Results were expressed as mean 士 
S.D. obtained from three independent experiments with duplicate wells 
for each condition. 
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4.4 Discussion 
Protein is considered as one of the major antiviral phytocompounds. 
Antiviral protein researches mainly focus on two major groups of proteins — RIPs 
and lectins. For lectins, interest has been mainly focused on anti-HIV activities and 
many monocot mannose-specific lectins, such as Cymbidium agglutinin (CA) from 
Cymbidium hybrid, List era ovata agglutinin (LOA) from L. ovata and Epipactis 
helleborine agglutinin (EHA) from E. helleborine, have been proven to possess in 
vitro antiviral activities against HIV as well as other enveloped viruses (Balzarini et 
al, 1992). A mannose-binding lectin Narcissus pseudonarcissus agglutinin (NPA) 
from N. pseudonarcissus has been isolated (Kaku et al, 1990) and shows marked in 
vitro inhibition to HIV and CMV (Balzarini et al., 1991). Therefore, it is possible 
that some other monocot lectins or proteins possess antiviral, including anti-RSV, 
activity. 
In this study, the proteins from the daffodils, including N. tazetta cultivar 
and N. tazetta var. chinensis, were examined for their anti-RSV activity. From the 
bulbs of N. tazetta cultivar, two mannose-binding proteins NTM2 and NTM3 were 
isolated after affinity and size-exclusion chromatography. The two proteins have 
different molecular mass as analyzed by SDS-PAGE. The first 20 N-terminal amino 
acid sequence of NTM2 shared a 45 % homology with that of NTL from N. tazetta 
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var. chinensis as analyzed by N-terminal amino acid sequencing. Both NTM2 and 
NTM3 are mannose-binding proteins, and whether they are lectins remain to be 
elucidated by testing their carbohydrate specificity, haemagglutinating activity, and 
study of their complete amino acid sequences. When tested for their ability on 
RSV-induced CPE inhibition, NTM2 and NTM3 only showed mild inhibitory effect. 
Besides, they were rather cytotoxic to HEp-2 cells. Therefore, they were not 
considered as potent anti-RSV agents. 
NTL from the bulbs of N. tazetta var. chinensis has been isolated, 
characterized and showed inhibition on bovine immunodeficiency virus (Ooi et al, 
2000). In the present study, NTL inhibited RSV-induced plaque formation (IC50 二 
2.30 |ig/ml), and its cytotoxicity to HEp-2 cells was not high (CC50 = 325 |ig/ml). Its 
high SI value of 141 indicated that it possesses potent anti-RSV activity. Further 
investigation on its mode of action revealed that significant reduction on number of 
plaques was observed when the lectin was either only present during the early 
infection phase or only present in the later infection phase, although the extent of 
inhibition under these two conditions were not as much as when the lectin was 
present during the whole infection cycle. As the early infection events were inhibited, 
NTL may be virucidal or, like some other antiviral lectins, interact with glycans on 
glycoproteins present on RSV envelope that are crucial for attachment or fusion and 
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prevented their normal functions. It has been showed that Urtica dioica agglutinin 
(UDA) from U. dioica strongly binds to the glycans on the HIV-1 attachment protein 
gpl20, and prevents HIV entry and transmission when being co-cultivated with 
persistently HIV-infected cells and uninfected cells in the lower jig/ml range 
(Balzarini, 2006). Some other lectins were also able to inhibit viral entry. Galanthus 
nivalis agglutinin (GNA), HHA, CA and UDA were found able to inhibit entry of 
HCV and HIV-1 to their target cells (Bertaux et al, 2007). Hippeastrum hybrid 
agglutinin (HHA) from Hippeastrum hybrid inhibits SARS-CoV replication when 
added at the moment of infection, and the lectin also able to inhibit extracellular 
viral load when added up to 5 hours post-infection (a time near the end of the virus 
replication cycle), thus HHA interacts both at vims entry and at virus release 
(Keyaerts et al, 2007). To inhibit RSV infection, the possible targets that NTL can 
bind are the glycoproteins present on RSV envelope. Three envelope glycoproteins 
are present on RSV, including the G protein, the F protein and the SH protein. The G 
protein of RSV Long strain contains 8 A^-glycosylation sites and up to 70 potential 
0-glycosylation acceptor sites (Rawling & Melero, 2007). The F protein contains six 
potential A^-glycosylation sites (Zimmer et al, 2001). The SH protein contains 
polylactosaminoglycan (Feldman et al, 2001). The properties of viral glycoproteins 
are heavily influenced by the nature, position, and extent of glycosylation. Both the 
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G and F proteins may be involved in the initial attachment of RSV to host cell, and 
the F protein is largely responsible for the subsequent fusion process, though highest 
level of fusion was observed when all three envelope glycoproteins are present 
(Feldman et al, 2001). Besides, although the cellular receptor for RSV still remains 
to be identified, interactions between G or F protein with cellular 
glycosaminoglycans (GAGs), including heparan sulfate, have been shown to be 
important for virus infectivity (Feldman et al, 2000; Hallak et al, 2000). If NTL 
binds to G or F protein, the interaction of the two glycoproteins with GAGs may be 
interfered and the attachment/fusion process may be hindered. This may explain the 
observed significant reduction on plaque formation when NTL was added during the 
infection phase only. Moreover, RSV glycoproteins expressed on infected cells at a 
later stage of the viral replication cycle may interact with GAGs expressed on 
neighboring uninfected cells, which may be responsible for the cell-to-cell fusion 
and syncytium formation (Feldman et al, 2001). This interaction may be blocked if 
the RSV glycoproteins were bound by NTL, and the spreading of RSV would be 
affected. In the present study, NTL was also found to reduce plaque formation when 
added only in the later infection phase. Whether NTL interfered with RSV spreading 
by binding to viral glycoproteins or inhibited other events during the viral 
replication or assembly processes remains to be elucidated. 
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Chapter 5 
General Discussion and Conclusions 
Respiratory syncytial virus infection remains a serious global health 
concern. Presently there is no licensed vaccine or effective drug available for the 
disease. The search for new therapy to the disease is urgently needed. Besides 
synthesis of novel antiviral compounds, natural products also serve as a major 
source of anti-RSV agents. In order to identify more naturally occurring anti-RSV 
agents, in the first part of the present project, two purified plant compounds, seven 
commercially available phytochemicals, as well as the water and ethanol extracts of 
nine medicinal plants were screened for their anti-RSV activities by observing their 
inhibition on RSV-induced cytopathic effect and their cytotoxicity were examined 
by MTT assay. A purified compound from W. indica, designated as daphnoretin, a 
purified lectin from Narcissus tazetta var. chinensis, designated as NTL, the ethanol 
extract of Adina pilulifera, as well as the ethyl acetate fraction of W. indica 
exhibited potent anti-RSV activities. Therefore, in the second part of the present 
study, the ethanol extract of A. pilulifera was further fractionated using petroleum 
ether, ethyl acetate and butanol. Among them, the ethyl acetate fraction was found as 
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the most potent anti-RSV fraction. Besides, as daphnoretin was isolated from the 
ethyl acetate fraction of JV. indica, it may partly explain the anti-RSV activity of the 
fraction. Thus, the IC50 of daphnoretin and the ethyl acetate fraction of A. pilulifera 
were further studied by plaque assay, and their SI were found to be 28.2 and 86.2, 
respectively, that are comparable to or higher than that of the positive control drug 
ribavirin (SI = 30.0). The modes of action of the samples were studied by the 
addition of compounds at different times during the virus infection cycle, so the 
samples were present during the early infection phase only (i.e. the first 2 h of 
infection only), during the whole infection cycle (i.e. throughout the whole 
experiment), or during the later infection phase only (i.e. after 2 h of infection). The 
antiviral activity of the A. pilulifera ethyl acetate fraction was found unlikely 
through inhibition of RSV attachment or penetration, but by inhibition of the later 
events of the virus replication cycle or by modulation of host cell's biological events. 
On the other hand, daphnoretin may be able to slightly inhibits viral attachment 
and/or fusion, and mainly inhibits later viral development and spreading. 
Daphnoretin was reported as a PKC activator (Ko et al, 1993; Wang et al, 1995; 
Chen et al, 1996) that leads to activation and translocation of intracellular PKC to 
the plasma membrane. At the same time, activation and translocation of PKCa to 
cell membrane was observed upon RSV contact and facilitates fusion 
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(San-Juan-Vergara et al, 2004). It is speculated that daphnoretin could compete with 
RSV for the intracellular PKC pool and affects RSV fusion. 
Many plant proteins have been reported for their antiviral activities against 
human viruses. Lectin is considered as one of the major groups of antiviral plant 
proteins. Different lectins have been shown for their antiviral activities against HIV, 
HCMV, HCV, influenza virus, poxvirus, HSV, RSV and SARS-CoV (Ooi et al, 
2004; Bertaux et al, 2007; Favacho et al, 2007; Kaur et al, 2007; Keyaerts et al, 
2007; Luo et al, 2007), and some of these studies focused on monocot 
mannose-binding lectins. Thus there is a potential for finding more antiviral, 
especially anti-RSV, lectins from monocots. Therefore, in the third part of the study, 
two proteins (NTM2, 15.2 kDa and NTM3, 6.70 kDa) were isolated from N. tazetta 
cultivar by ammonium sulfate precipitation, affinity chromatography on 
mannose-agarose column and size exclusion chromatography on Superose 12 FPLC 
column. N-terminal amino acid sequence of the two proteins were analyzed and 
compared to that of NTL, which was found to possess anti-RSV activity in the first 
part of the present study. The sequence of the first 20 N-terminal amino acids of 
NTM2 showed a 45 % homology with that of NTL, while the sequence of NTM3 
obtained was too short for comparison. Thus, NTM2 may, like NTL, belongs to the 
monocot mannose-binding lectin superfamily. In vitro antiviral study showed that 
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NTM2 and NTM3 only have mild anti-RSV effect and they are rather cytotoxic to 
HEp-2 cells. On the contrary, NTL potently inhibited RSV and has low cytotoxicity. 
The IC50 of NTL is 2.30 |ig/ml and its SI is 141.36, which is much higher than that 
of the positive control drug ribavirin. Further investigation on its mode of action 
revealed that significant reduction on number of plaques was observed when NTL 
was either only present during the early infection phase or only present in the later 
infection phase. NTL may, similar to some other anti-HIV lectins, able to recognize 
and bind to RSV envelope glycoproteins on the vims and on host cells, thereby 
interfere with the normal function of the glycoproteins and affect RSV attachment, 
fusion, syncytium formation and spreading. 
Further studies could be directed to the isolation and characterization of 
pure antiviral compound(s) from the A. pilulifera ethyl acetate fraction and more 
in-depth investigations on the antiviral mechanisms of the pure compound, 
daphnoretin, and NTL could be carried out. More than one method should be 
employed for both anti-RSV and cytotoxicity assays so as to confirm the results. 
Moreover, more in vitro cytotoxicity tests using a panel of both primary and 
continuous cell lines as well as understanding of any known toxicity or adverse 
effects of the compounds are needed before proceeding to in vivo or pre-clinical 
testing. Besides, as NTL is a protein, it is also important to test for the occurrence of 
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any unfavorable protein properties such as allergenicity, haemagglutination and 
unwanted interaction of the lectin with cellular glycoproteins. 
In conclusion, the ethyl acetate fraction of A. pilulifera, daphnoretin and 
NTL were shown for the first time that they possess anti-RSV activity. The three 
candidates exhibited different modes of action. This study provided some scientific 
information for the future development of the three candidates as potential anti-RSV 
drugs. Further in vivo studies and in-depth investigation on their antiviral 
mechanisms could be implemented to provide more information on their efficacy 
and safety. 
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